Prostate cancer detection
Novel DNA methylation markers and panels enhance prostate cancer detection by distinguishing cancerous from benign tissues and grading severity, improving diagnostic accuracy and reducing overdiagnosis.
Patent Information
- Application Number
- JP2025072146
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-02-28
- Filing Date
- 2025-04-24
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2038-02-27
AI Technical Summary
Current prostate cancer screening methods, particularly PSA testing, lead to overdiagnosis and unnecessary treatment of lower-risk tumors, necessitating the development of novel biomarkers for accurate and specific detection.
Identification of 73 novel DNA methylation markers and marker panels that distinguish prostate cancer tissue from benign tissue, and 10 markers that differentiate high-grade from low-grade prostate cancer, using next-generation sequencing and methylation-specific PCR assays.
Provides high specificity and sensitivity for prostate cancer detection, enabling earlier and more accurate diagnosis and reducing unnecessary treatments.
Smart Images

Figure 0007949098000001 
Figure 0007949098000002 
Figure 0007949098000003
Abstract
Description
TECHNICAL FIELD
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 464,800 filed on February 28, 2017, the entire content of which is incorporated herein by reference in its entirety.
[0002] Provided herein are technologies for prostate cancer screening, in particular, but not exclusively, methods, compositions, and related uses for detecting the presence of prostate cancer.
BACKGROUND ART
[0003] Prostate cancer (PCa) is the second most commonly diagnosed cancer among men, accounting for 903,000 new cases and 258,000 deaths worldwide in 2008. While PCa is common, the disease is also heterogeneous in clinical behavior. It is estimated that approximately 1 in 6 American men will be diagnosed with PCa, yet the mortality rate of PCa among American men is only 2.8% (1 in 36 men) (see, for example, Strand SH, et al., Int J Mol Sci 2014;15:16544-16576).
[0004] PCA survival rates depend on many factors. Earlier diagnosis of the disease, when it is not progressing significantly, provides most men with the best chance of curative treatment. In fact, earlier PCA diagnosis is facilitated by the use of prostate-specific antigen (PSA) testing. PSA testing at the time when PCA is progressing in stage and malignancy leads to the identification of disease with more room for curative treatment. While PSA is beneficial in the diagnosis and management of PCA, screening with PSA is also considered controversial. Screening with PSA may lead to the diagnosis of lower-grade, lower-risk tumors, and subsequent overtreatment may cause men unnecessary harm to their quality of life (erectile dysfunction, incontinence). Consequently, novel biomarkers are needed to aid in the diagnosis of PCA. Novel tests are also needed to give men improved prognostic information about their cancer.
[0005] This invention addresses these needs. [Overview of the Initiative]
[0006] Methylated DNA has been studied as a potential class of biomarkers in tissues of most tumor types. In many cases, DNA methyltransferases add methyl groups to DNA at cytosine-phosphate-guanine (CpG) island sites as an epigenetic regulation of gene expression. In the biological attraction mechanism, methylation events obtained in the promoter regions of tumor suppressor genes are thought to arrest expression and thus contribute to carcinogenesis. DNA methylation can be a more chemically and biologically stable diagnostic tool than RNA or protein expression (Laird (2010) Nat Rev Genet 11:191-203). Furthermore, in other cancers such as sporadic colorectal cancer, methylation markers exhibit superior specificity and have broader informational value and sensitivity than individual DNA mutations (Zou et al (2007) Cancer Epidemiol Biomarkers Prev 16:2686-96).
[0007] Analysis of CpG islands yields important insights when applied to animal models and human cell lines. For example, Zhang and colleagues found that amplicons from different parts of the same CpG island can have different levels of methylation (Zhang et al. (2009) PLoS Genet 5:e1000438). Furthermore, the methylation levels were distributed bimodally between highly methylated and unmethylated sequences, further supporting a binary switch-like pattern of DNA methyltransferase activity (Zhang et al. (2009) PLoS Genet 5:e1000438). Analysis of in vivo mouse tissues and in vitro cell lines demonstrated that only promoters with high CpG density (HCP, defined as having >7% CpG sequences within a 300-base pair region) were methylated, while regions with low CpG density (LCP, defined as having <5% CpG sequences within a 300-base pair region) tended to be frequently methylated in a dynamic tissue-specific pattern (Meissner et al. (2008) Nature 454:766-70). HCPs include promoters for ubiquitous housekeeping genes and highly regulated developmental genes. Several established markers, such as Wnt2, NDRG2, SFRP2, and BMP3, were methylated to >50% between HCP sites (Meissner et al. al. (2008) Nature 454:766-70).
[0008] Epigenetic methylation of DNA at cytosine-phosphate-guanine (CpG) island sites by DNA methyltransferases has been studied as a potential class of biomarkers in most tumor-type tissues. In the biological attraction mechanism, methylation events obtained in the promoter regions of tumor suppressor genes are thought to arrest expression and contribute to carcinogenesis. DNA methylation can be a more chemically and biologically stable diagnostic tool than RNA or protein expression. Furthermore, in other cancers such as sporadic colorectal cancer, abnormal methylation markers are more broadly informative, highly sensitive, and exhibit superior specificity than individual DNA mutations.
[0009] Several methods are available for the search for novel methylation markers. Microarray-based matching of CpG methylation is a reasonable and high-throughput approach, but this approach is biased towards known areas of interest, mainly established tumor suppressor promoters. Alternative methods for genome-wide analysis of DNA methylation have been developed over the past decade. There are three basic approaches. The first approach involves digesting DNA with restriction enzymes that recognize specific methylation sites, followed by several possible analytical techniques to provide methylation data restricted to enzyme-recognized sites or primers, and then amplifying the DNA in a quantification step (methylation-specific PCR; MSP, etc.). The second approach involves enriching methylation fractions of genomic DNA using antibodies targeting methyl-cytosine or other methyl-specific binding domains, followed by microarray analysis or sequencing to map the fragments to a reference genome. This approach does not provide single-nucleotide resolution for all methylation sites within the fragment. A third approach begins with bisulfite treatment of DNA, converting all unmethylated cytosines to uracil, followed by restriction enzyme digestion and coupling to adapter ligands, after which sequencing of all fragments is completed. The selection of restriction enzymes can enrich fragments for CpG-density regions and reduce the number of redundant sequences that can be mapped to multiple gene locations during analysis.
[0010] RRBS yields CpG methylation status data at single-nucleotide resolution for 80–90% of all CpG islands, and most tumor suppressor promoters at moderate to high read coverage. In cancer case-control studies, analysis of these reads leads to the identification of variable methylation regions (DMRs). In previous RRBS analyses of pancreatic cancer specimens, hundreds of DMRs were not covered, many of which had not been associated with carcinogenesis, and many of which were not annotated. Furthermore, validation studies in independent tissue sample sets confirmed the marker CpG with 100% sensitivity and specificity in terms of performance.
[0011] Provided herein are scientific and technical aspects of prostate cancer screening, including, but not exclusively, methods, compositions, and related applications for detecting the presence of prostate cancer.
[0012] Indeed, as described in Examples I–VIII, experiments conducted during the process of identifying embodiments of the present invention identified a novel set of 73 variable methyl regions (DMRs) to distinguish cancerous prostate-derived DNA from non-neoplastic control DNA. In addition, 10 novel DMRs were identified that are methylated in prostate epithelium (cancerous and normal) but not in normal leukocyte DNA samples. Both sets of these regions were identified from next-generation sequencing studies of CpG, enriched with tumor and normal DNA converted to bisulfite. Tumor samples included low-grade Gleason 6 and high-grade Gleason 7+ patterns. DMRs were selected using proprietary filtering and analysis and validated in independent sets of tissue samples using novel methylation-specific PCR (MSP) assays. These 73 biomarker assays demonstrated excellent detection in tissue and possessed broad clinical specificity (some for cancers across many different organ sites, others specific only to prostate cancer).
[0013] These experiments list and describe 120 novel DNA methylation markers (Table 1) that distinguish prostate cancer tissue from benign prostate tissue. From these 120 novel DNA methylation markers, further experiments identified 73 markers that can distinguish high-grade prostate cancer tissue (e.g., Gleason score 7+) from benign prostate tissue. More specifically, we identified markers and / or marker panels (e.g., chromosomal regions with annotations selected from ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1.61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047) that could distinguish prostate cancer tissue from benign prostate tissue (see Examples I-VI).
[0014] Additional experiments conducted during the development of embodiments of the present invention have shown that markers capable of distinguishing prostate cancer tissue from benign prostate tissue (e.g., SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425, MAX.chr3.193, MAX.chr2.971_3164, MAX.chr3.727_8028, HES5_0840, TPM4_8037, SLCO) can be used. The goal was to identify chromosomal regions with annotations selected from 3A1_6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487. These markers were able to distinguish prostate cancer tissue from benign prostate tissue (Example VIII; see Table 11).
[0015] Additional experiments conducted during the development of embodiments of the present invention focused on identifying markers (e.g., chromosomal regions with annotations selected from SERPINB9_3479, GRASP_0932, SLCO3A1_6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, WNT3A_5487) that can distinguish high-grade prostate cancer tissue (e.g., Gleason score 7+) from low-grade prostate cancer tissue (e.g., Gleason score 6), and these markers were able to distinguish prostate cancer tissue from benign prostate tissue (Example VIII; see Table 11).
[0016] Additional experiments conducted during the development of embodiments of the present invention focused on identifying markers capable of detecting the presence or absence of prostate cancer in blood samples (e.g., blood plasma samples). In fact, markers and / or marker panels (e.g., chromosomal regions with annotations selected from max.chr3.193, HES5, SLCO3A1, and TPM4_8047) were identified that could detect the presence or absence of prostate cancer tissue in blood plasma samples (see Examples I-VI).
[0017] As described herein, this technology provides multiple methylated DNA markers and subsets thereof (e.g., sets of 2, 3, 4, 5, 6, 7, or 8 markers) that have high distinction for prostate cancer as a whole. Experiments have applied selection filters to candidate markers to identify markers that provide a high signal-to-noise ratio and low background levels, thus providing high specificity for prostate cancer screening or diagnostic purposes.
[0018] In some embodiments, this technique relates to evaluating the presence of one or more markers specified herein and their methylation status in biological samples (e.g., prostate tissue, plasma samples). These markers include one or more variable methylation regions (DMRs), as considered herein, for example, as provided in Tables 1 and 3. In embodiments of this technique, the methylation status is evaluated. As such, the techniques provided herein are not limited to methods for measuring the methylation status of genes. For example, in some embodiments, the methylation status is measured by genome scanning methods. For example, one method includes restriction landmark genome scanning (Kawai et al. (1994) Mol. Cell. Biol. 14:7421-7427), and another example includes methylation-sensitive arbitrary prime PCR (Gonzalgo et al. (1997) Cancer Res. 57:594-599). In some embodiments, changes in the methylation pattern at specific CpG sites are monitored by Southern analysis of the region of interest after digestion of genomic DNA with methylation-sensitive restriction enzymes (digested Southern method). In some embodiments, analyzing changes in methylation patterns involves PCR-based processes that include digestion of genomic DNA with methylation-sensitive restriction enzymes before PCR amplification (Singer-Sam et al. (1990) Nucl. Acids Res. 18:687). In addition, other scientific techniques utilizing bisulfite treatment of DNA as a starting point for methylation analysis have been reported. These include methylation-specific PCR (MSP) (Herman et al. (1992) Proc. Natl. Acad. Sci. USA 93:9821-9826) and restriction enzyme digestion of PCR products amplified from bisulfite-converted DNA (Sadri and Hornsby (1996) Nucl. Acids Res. 24:5058-5059; and Xiong and Laird (1997) Nucl. Acids Res. 25:2532-2534).PCR technology has been developed for the detection of gene mutations (Kuppuswamy et al. (1991) Proc. Natl. Acad. Sci. USA 88:1143-1147) and the quantification of allele-specific expression (Szabo and Mann (1995) Genes Dev. 9:3097-3108; and Singer-Sam et al. (1992) PCR Methods Appl. 1:160-163). These techniques utilize internal primers, anneal to a template generated for PCR, and terminate immediately at the 5' of the single nucleotide being assayed. Methods using a “quantitative Ms-SNuPE assay,” such as that described in U.S. Patent No. 7,037,650, are employed in several embodiments.
[0019] When evaluating methylation status, this methylation status is often expressed as the percentage of individual strands of DNA that are methylated at a specific site (e.g., in a single nucleotide, in a specific region or locus, in a longer sequence of interest, e.g., up to subsequences of approximately 100-bp, 200-bp, 500-bp, or 1000-bp in length of more than one DNA) compared to the total population of DNA in the sample containing that specific site. Conventionally, the amount of unmethylated nucleic acid is determined by PCR using a calibrator. The known amount of DNA is then treated with bisulfite, and the resulting methylation-specific sequence is determined using either real-time PCR or other exponential amplification, such as the QuARTS assay (e.g., provided by U.S. Patent No. 8,361,720, and U.S. Patent Application Publications 2012 / 0122088 and 2012 / 0122106, as incorporated herein by reference).
[0020] For example, in some embodiments, these methods involve generating a standard curve for unmethylated targets by using an external standard. This standard curve consists of at least two points and relates the real-time Ct value for unmethylated DNA to a known quantitative standard. Next, a second standard curve for methylated targets consists of at least two points and an external standard. This second standard curve relates the Ct for methylated DNA to a known quantitative standard. Next, the Ct values of test samples for the methylated population and the unmethylated population are determined, and the genomic equivalent of DNA is calculated from the standard curves generated by the first two steps. The rate of methylation at the site of interest is calculated from the amount of methylated DNA proportional to the total amount of DNA in the population, for example, (number of methylated DNAs) / (number of methylated DNAs + number of unmethylated DNAs) × 100.
[0021] Also provided herein are compositions and kits for carrying out these methods. For example, in some embodiments, reagents specific to one or more markers (e.g., primers, probes) are provided individually or in sets (e.g., sets of primer pairs for amplifying multiple markers). Additional reagents for performing detection assays (e.g., enzymes, buffers, positive and negative controls for performing QuARTS, PCR, sequencing, bisulfite, or other assays) can also be provided. In some embodiments, kits containing one or more reagents sufficient or useful to carry out the methods are provided. Also provided are reaction mixtures containing these reagents. Furthermore, master mix reagent sets containing multiple reagents that can be added to each other and / or to a test sample to complete the reaction mixture are also provided.
[0022] In some embodiments, the technology described herein relates to a programmable machine designed to perform an array of arithmetic or logical operations, such as those provided by these methods described herein. For example, some embodiments of the technology relate to computer software and / or computer hardware (e.g., implemented therein). In one embodiment, the technology relates to a computer, which includes a form of memory, elements for performing arithmetic and logical operations, and processing elements (e.g., a microprocessor) for performing a series of instructions (e.g., methods provided herein) for reading, manipulating, and storing data. In some embodiments, the microprocessor determines the methylation status (e.g., DMR1-140 of one or more DMRs, as provided in Tables 1 and 13); compares the methylation status (e.g., DMR1-140 of one or more DMRs, as provided in Tables 1 and 13); generates a standard curve; determines the Ct value; calculates the methylation fraction, frequency, or percentage (e.g., DMR1-140 of one or more DMRs, as provided in Tables 1 and 13); identifies CpG islands; determines the specificity and / or sensitivity of the assay or marker; calculates the ROC curve and associated AUC; sequences the analysis; and is part of the system as described herein or known in the art.
[0023] In some embodiments, a microprocessor or computer uses methylation status data in an algorithm to predict the location of cancer.
[0024] In some embodiments, a software or hardware component receives the results of multiple assays, determines a single-value result, and reports to the user an indication of cancer risk based on the results of the multiple assays (e.g., determining the methylation status of multiple DMRs, as provided in Tables 1 and 3). Related embodiments calculate a risk factor based on a mathematical combination (e.g., weighted combination, linear combination) of results from multiple assays, such as determining the methylation status of multiple markers (e.g., multiple DMRs, as provided in Tables 1 and 3). In some embodiments, the methylation status of DMRs can define dimensions and have values in a multidimensional space, and the coordinates defined by the methylation status of multiple DMRs are results, for example, related to cancer risk, to be reported to the user.
[0025] Some embodiments include storage media and memory components. Memory components (e.g., volatile and / or non-volatile memory) find use in storing instructions (e.g., embodiments of processes as provided herein) and / or data (e.g., workpieces such as methylation measurements, sequences, and associated statistical descriptions). Some embodiments also relate to systems including one or more of a CPU, a graphics card, and a user interface (e.g., including output devices such as a display and input devices such as a keyboard).
[0026] This science and technology and related programmable machines include conventional existing science and technology, as well as science and technology under development or already developed (e.g., quantum computers, chemical computers, DNA computers, optical computers, spintronics-based computers, etc.).
[0027] In some embodiments, the disclosed technology includes wired (e.g., metal cables, optical fibers) or wireless transmission media for transmitting data. For example, some embodiments relate to data transmission via a network (e.g., a local area network (LAN), a wide area network (WAN), an ad hoc network, the Internet, etc.). In some embodiments, programmable machines exist on a network as peers, and in some embodiments, the programmable machines have a client / server relationship.
[0028] In some embodiments, data is stored on a computer-readable storage medium such as a hard disk, flash memory, optical medium, or floppy disk.
[0029] In some embodiments, the technology provided herein is associated with a plurality of programmable devices that operate in concert to perform the methods as described herein. For example, in some embodiments, a plurality of computers (e.g., connected by a network) can operate in parallel to collect and process data in an implementation of cluster computing, grid computing, or some other distributed computer architecture that relies on full computers (on-board CPU, storage, power supply, network interface, etc.) connected to a network (private, public, or the Internet) via conventional network interfaces such as Ethernet (registered trademark) and optical fibers, or via wireless network technologies.
[0030] For example, some embodiments provide a computer including a computer-readable medium. The embodiments include random access memory (RAM) coupled to a processor. The processor executes computer-executable program instructions stored in the memory. Such processors may include microprocessors, ASICs, state machines, or other processors, and can be any of several computer processors, such as processors from Intel Corporation in Santa Clara, California, and Motorola Corporation in Schaumburg, Illinois. Such processors may include, or communicate with, a medium, such as a computer-readable medium, which stores instructions that, when executed by the processor, cause the processor to perform the steps described herein.
[0031] Embodiments of computer-readable media include, but are not limited to, electronic, optical, magnetic, or other storage or transmission devices capable of providing a processor containing computer-readable instructions. Other examples of suitable media include, but are not limited to, floppy disks, CD-ROMs, DVDs, magnetic disks, memory chips, ROMs, RAMs, ASICs, configured processors, all optical media, all magnetic tapes or other magnetic media, or any other media from which a computer processor can read the instructions. Furthermore, various other forms of computer-readable media can transmit or carry instructions to a computer, including both wired and wireless routers, private or public networks, or other transmission devices or channels. These instructions may consist of code from any suitable computer programming language, including, for example, C, C++, C#, Visual Basic, Java®, Python, Perl, and JavaScript®.
[0032] In some embodiments, the computer is connected to a network. The computer may also include multiple external or internal devices, such as a mouse, CD-ROM, DVD, keyboard, display, or other input or output devices. Examples of computers include personal computers, digital assistants, personal digital assistants, cellular phones, mobile phones, smartphones, pagers, digital tablets, laptop computers, internet appliances, and other processor-based devices. Generally, these computers relating to the aspects of the science and technology provided herein may be any type of processor-based platform, which runs on any operating system such as Microsoft Windows, Linux®, UNIX®, or Mac OS X, and can support one or more programs including the science and technology provided herein. Some embodiments include personal computers that run other application programs (e.g., applications). These applications may be contained in memory and can be run by a client device, for example, and may include word processing applications, spreadsheet applications, email applications, instant messenger applications, presentation applications, internet browser applications, calendar / organizer applications, and any other applications.
[0033] All such components, computers, and systems described herein in relation to science and technology may be logical or virtual.
[0034] As a result, provided herein is a scientific technique relating to a method for screening for prostate cancer in a sample obtained from a subject, the method comprising assaying the methylation status of a marker in a sample obtained from a subject (e.g., prostate tissue) (e.g., plasma sample), and identifying a subject having prostate cancer when the methylation status of the marker differs from the methylation status of the marker assayed in a subject without prostate cancer, wherein the marker contains a base in a variable methylation region (DMR) selected from the group consisting of 1 to 140 variable methylation regions as provided in Tables 1 and 13.
[0035] In some embodiments where the sample obtained from the subject is prostate cancer, the marker is selected from ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1.61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047.
[0036] In some embodiments, where the sample obtained from the subject is prostate cancer, this marker is SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425, MAX.chr3.193, MAX.chr2.971_3164, MAX.chr3.727_ Selected from 8028, HES5_0840, TPM4_8037, SLCO3A1_6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487.
[0037] In some embodiments where the sample obtained from the subject is blood plasma, the marker is selected from max.chr3.193, HES5, SLCO3A1, and TPM4_8047.
[0038] This technology relates to identifying and differentiating prostate cancer. Some embodiments provide methods comprising assaying multiple markers, for example, methods comprising assaying 2 to 11 to 100 or 140 markers.
[0039] This scientific technique is not limited to the methylation state being assayed. In some embodiments, assaying the methylation state of a marker in a sample comprises determining the methylation state of a single base. In some embodiments, assaying the methylation state of a marker in a sample comprises determining the degree of methylation at multiple bases. Furthermore, in some embodiments, the methylation state of the marker comprises increased methylation of the marker compared to the normal methylation state of the marker. In some embodiments, the methylation state of the marker comprises decreased methylation of the marker compared to the normal methylation state of the marker. In some embodiments, the methylation state of the marker comprises a different pattern of methylation of the marker compared to the normal methylation state of the marker.
[0040] Furthermore, in some embodiments, the marker is a region of 100 or fewer bases, a region of 500 or fewer bases, a region of 1000 or fewer bases, a region of 5000 or fewer bases, or in some embodiments, the marker is a single base. In some embodiments, the marker is located in a promoter with a high CpG density.
[0041] This technology is not limited by the type of sample. For example, in some embodiments, the sample may be a fecal sample, a tissue sample (e.g., prostate tissue sample), a blood sample (e.g., plasma, serum, whole blood), excrement, or a urine sample.
[0042] Furthermore, this technology is not limited to the methods used to determine the methylation state. In some embodiments, the assay comprises using methylation-specific polymerase chain reactions, nucleic acid sequencing, mass spectrometry, methylation-specific nucleases, mass-based separation, or target capture. In some embodiments, the assay comprises using methylation-specific oligonucleotides. In some embodiments, this technology determines the methylation state using massively parallel sequencing (e.g., next-generation sequencing), such as synthesis sequencing, real-time (e.g., single-molecule) sequencing, bead emulsion sequencing, or nanopore sequencing.
[0043] This technology provides reagents for detecting DMRs, and as such reagents, for example, in some embodiments, provides a set of oligonucleotides containing sequences provided by SEQ ID NOs: 1-146 and / or SEQ ID NOs: 147-234. In some embodiments, provides oligonucleotides containing sequences complementary to chromosomal regions containing bases in DMRs, for example, oligonucleotides sensitive to the methylation state of DMRs.
[0044] This technology provides a variety of markers, for example, in some embodiments, these markers include ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1.61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047, and also includes chromosomal regions having annotations containing the markers (see Examples I-VI).
[0045] In some embodiments, this marker is SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425, MAX.chr3.193, MAX.chr2.971_3164, MAX.chr3.727_8028, HES5_0840, TPM4_8037, SLCO These include 3A1_6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487, and also include chromosomal regions having annotations including markers (see Example VIII).
[0046] In some embodiments, the obtained sample is a plasma sample, and the markers are max.chr3.193, HES5, SLCO3A1, and TPM4_8047, and also includes a chromosomal region having annotations containing the markers.
[0047] The present invention provides embodiments of the kit, for example, a kit comprising a bisulfite reagent and a control nucleic acid, wherein the control nucleic acid comprises a sequence from a DMR selected from the group consisting of DMR1-140 (from Table 1 or 13) and has a methylation state associated with subjects without prostate cancer. In some embodiments, these kits comprise a bisulfite reagent and an oligonucleotide as described herein. In some embodiments, these kits comprise a bisulfite reagent and a control nucleic acid, wherein the control nucleic acid comprises a sequence from a DMR selected from the group consisting of DMR1-140 (from Table 1 or 13) and has a methylation state associated with subjects with prostate cancer. Some embodiments of the kits comprise a sample collector for obtaining a sample from a subject (e.g., a fecal sample, a prostate tissue sample, a plasma sample), a reagent for isolating nucleic acid from this sample, a bisulfite reagent, and an oligonucleotide, as described herein.
[0048] This scientific technology relates to embodiments of compositions (e.g., reaction mixtures). In some embodiments, compositions comprising nucleic acids containing DMR and bisulfite reagents are provided. In some embodiments, compositions comprising nucleic acids containing DMR and oligonucleotides, as described herein. In some embodiments, compositions comprising nucleic acids containing DMR and methylation-sensitive restriction enzymes are provided. In some embodiments, compositions comprising nucleic acids containing DMR and polymerases are provided.
[0049] The present invention provides embodiments of additional relevant methods for screening for prostate cancer in samples obtained from subjects (e.g., prostate tissue samples, plasma samples, fecal samples), for example, the method comprising determining the methylation status of a marker in a sample containing a base in a DMR which is one or more of DMRs 1-140 (from Table 1 or 13), comparing the methylation status of the marker from the subject sample with that of a normal control sample from a subject without prostate cancer, and determining the confidence interval and / or p-value of the difference in methylation status between the subject sample and the normal control sample. In some embodiments, the confidence interval is 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9%, or 99.99%, and the p-value is 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001, or 0.0001. Some embodiments of these methods provide the steps of: reacting a nucleic acid containing DMR with a bisulfite reagent to produce a nucleic acid reacted with bisulfite; sequencing the nucleic acid reacted with bisulfite to provide the nucleotide sequence of the nucleic acid reacted with bisulfite; comparing the nucleotide sequence of the nucleic acid reacted with bisulfite with the nucleotide sequence of a nucleic acid containing DMR from a subject without prostate cancer to identify differences between the two sequences; and identifying a subject with prostate cancer when differences are present.
[0050] This technology provides a system for screening for prostate cancer in samples obtained from subjects. Exemplary embodiments of the system include, for example, a system for screening for prostate cancer in samples obtained from subjects (e.g., prostate tissue samples, plasma samples, fecal samples), the system comprising an analytical component configured to determine the methylation status of the sample, a software component configured to compare the methylation status of the sample with the methylation status of a control or reference sample recorded in a database, and a warning component configured to alert the user to methylation status associated with prostate cancer. In some embodiments, the software component receives results from multiple assays (e.g., multiple markers, e.g., determining the methylation status of DMRs, as provided in Table 1 or 3), calculates values or results for a report based on the multiple results, and determines a warning. Some embodiments provide a database of weighted parameters associated with each DMR provided herein for use in calculating values or results, and / or for use in warnings to inform a user (e.g., a physician, nurse, clinician, etc.). In some embodiments, all results from multiple assays are reported, and in some embodiments, one or more results are used to provide a score, value, or result based on a composite of one or more results from multiple assays indicating cancer risk in a subject.
[0051] In some embodiments of the system, the sample comprises nucleic acids containing DMR. In some embodiments, the system further comprises components for sample collection, such as components for isolating nucleic acids and components for collecting fecal samples. In some embodiments, the system comprises nucleic acid sequences containing DMR. In some embodiments, the database comprises nucleic acid sequences from subjects who do not have prostate cancer. Also provided is nucleic acids, for example, a set of nucleic acids, each nucleic acid comprising a sequence containing DMR. In some embodiments of this set of nucleic acids, each nucleic acid comprises a sequence from a subject who does not have prostate cancer. Embodiments of the related system comprise a set of nucleic acids as described, and a database of nucleic acid sequences associated with this set of nucleic acids. Some embodiments further comprise a bisulfite reagent. And some embodiments further comprise a nucleic acid sequencer.
[0052] In certain embodiments, a method is provided for characterizing samples from human patients (e.g., prostate tissue samples, plasma samples, fecal samples). For example, in some embodiments, such embodiments include obtaining DNA from a human patient sample, assaying the methylation status of DNA methylation markers containing bases in variable methylation regions (DMRs) selected from the group consisting of DMR1 to 140 from Table 1 or 13, and comparing the assayed methylation status of one or more DNA methylation markers to a methylation level standard for one or more DNA methylation markers for human patients without prostate cancer.
[0053] These methods are not limited to specific types of samples from human patients. In some embodiments, the sample is a prostate tissue sample. In some embodiments, the sample is a plasma sample. In some embodiments, the sample is a fecal sample, tissue sample, prostate tissue sample, blood sample, or urine sample.
[0054] In some embodiments, such methods include assaying multiple DNA methylation markers. In some embodiments, such methods include assaying 2 to 11 DNA methylation markers. In some embodiments, such methods include assaying 12 to 140 DNA methylation markers. In some embodiments, such methods include assaying the methylation status of one or more DNA methylation markers in a sample and determining the methylation status of a single base. In some embodiments, such methods include assaying the methylation status of one or more DNA methylation markers in a sample and determining the degree of methylation at multiple bases. In some embodiments, such methods include assaying the forward methylation status or the reverse methylation status.
[0055] In some embodiments, this DNA methylation marker is a single region of 100 or fewer bases. In some embodiments, this DNA methylation marker is a single region of 500 or fewer bases. In some embodiments, this DNA methylation marker is a single region of 1000 or fewer bases. In some embodiments, this DNA methylation marker is a single region of 5000 or fewer bases. In some embodiments, this DNA methylation marker is a single base. In some embodiments, this DNA methylation marker is located in a promoter with a high CpG density.
[0056] In some embodiments, the assay comprises using methylation-specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nuclease, mass-based separation, or target capture.
[0057] In some embodiments, the assay comprises the use of a methylation-specific oligonucleotide. In some embodiments, this methylation-specific oligonucleotide is selected from the group consisting of SEQ ID NOs: 1 to 146 and / or SEQ ID NOs: 147 to 234.
[0058] In some embodiments, chromosomal regions having annotations selected from the group consisting of ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1.61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047 contain DNA methylation markers. In some embodiments, these DMRs are taken from Table 3.
[0059] In some embodiments, SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425, MAX.chr3.193, MAX.chr2.971_3164, MAX.chr3.727_8028, HES5_0840, TPM4_8037, SLCO3A1 Chromosomal regions having annotations selected from the group consisting of _6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487 contain DNA methylation markers.
[0060] In some embodiments, the obtained sample is a plasma sample, and the markers are max.chr3.193, HES5, SLCO3A1, and TPM4_8047, and also includes a chromosomal region having annotations containing the markers.
[0061] In some embodiments, such methods comprise determining the methylation status of two DNA methylation markers. In some embodiments, such methods comprise determining the methylation status of a pair of DNA methylation markers provided in the rows of Table 1 or 3.
[0062] In certain embodiments, this technology provides a method for characterizing samples obtained from human patients. In some embodiments, such methods include determining the methylation status of a DNA methylation marker in a sample containing a base in a DMR selected from the group consisting of DMR1 to 140 from Tables 1 and 13; comparing the methylation status of the DNA methylation marker from a patient sample with the methylation status of the DNA methylation marker from a normal control sample from a human subject without prostate cancer; and determining the confidence interval and / or p-value of the difference in methylation status between the human patient and the normal control sample. In some embodiments, the confidence interval is 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9%, or 99.99%, and the p-value is 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001, or 0.0001.
[0063] In a particular embodiment, this technology provides a method for characterizing a sample obtained from a human subject (e.g., a prostate tissue sample, a plasma sample, or a fecal sample), the method comprising: reacting a nucleic acid containing DMR with a bisulfite reagent to produce a nucleic acid reacted with bisulfite; sequencing the nucleic acid reacted with bisulfite to provide the nucleotide sequence of the nucleic acid reacted with bisulfite; and comparing the nucleotide sequence of the nucleic acid reacted with bisulfite with the nucleotide sequence of a nucleic acid containing DMR from a subject without prostate cancer to identify the differences between the two sequences.
[0064] In certain embodiments, this technology provides a system for characterizing samples obtained from human subjects (e.g., prostate tissue samples, plasma samples, fecal samples), the system comprising an analytical component configured to determine the methylation status of the sample, a software component configured to compare the methylation status of the sample with the methylation status of a control or reference sample recorded in a database, and a warning component configured to determine a single value based on a combination of methylation statuses and to warn users of methylation statuses associated with prostate cancer. In some embodiments, the sample comprises nucleic acids containing DMRs.
[0065] In some embodiments, such systems further include components for isolating nucleic acids. In some embodiments, such systems further include components for collecting samples.
[0066] In some embodiments, the sample is a fecal sample, a tissue sample, a prostate tissue sample, a blood sample, or a urine sample. In some embodiments, the database includes nucleic acid sequences containing DMRs. In some embodiments, the database includes nucleic acid sequences from subjects who do not have prostate cancer.
[0067] Based on the teachings contained herein, additional embodiments will be obvious to those skilled in the art. [Modes for carrying out the invention]
[0068] Provided herein are scientific and technical aspects relating to prostate cancer screening, including, but not exclusively, methods, compositions, and related uses for detecting the presence of prostate cancer. Where such scientific and technical aspects are described herein, the section headings used are for organizational purposes only and should not be construed as limiting the subject matter of the invention in any way.
[0069] In this detailed description of various embodiments, many specific details are given for illustrative purposes to provide a complete understanding of the disclosed embodiments. However, those skilled in the art will understand that these various embodiments can be carried out with or without these specific details. In other examples, structures and devices are shown in block diagram form. Furthermore, those skilled in the art will readily understand that the specific order in which these methods are presented and performed is illustrative, and that any changes to this order may still remain within the spirit and scope of the various embodiments disclosed herein.
[0070] All documents and similar materials cited herein, including but not limited to patents, patent applications, articles, books, papers, and internet web pages, are expressly incorporated by reference in their entirety for all purposes. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to whom the various embodiments described herein belong. Where, when the definitions of these terms appear to differ from those provided in the teachings of the invention, the definitions provided in the teachings of the invention shall prevail.
[0071] definition To facilitate understanding of the science and technology of this invention, numerous terms and phrases are defined below. Further definitions are provided throughout the detailed description.
[0072] Throughout this specification and the claims, the following terms have the meanings expressly associated with this specification unless the context clearly indicates otherwise. The phrase “in one embodiment” as used herein does not necessarily refer to the same embodiment, but it may. Furthermore, the phrase “in another embodiment” as used herein does not necessarily refer to a different embodiment, but it may. Thus, various embodiments of the present invention can be readily combined without departing from the scope or spirit of the invention, as described below.
[0073] In addition, as used herein, unless the context explicitly indicates otherwise, the term “or” is an inclusive “or” operator and is equivalent to the term “and / or”. The term “based on” allows for a basis on additional factors not listed, unless the context explicitly indicates otherwise. In addition, throughout this specification, “a,” “an,” and “the” include plural referents. The meaning of “in” includes “inside” and “on top.”
[0074] As used herein, “nucleic acid” or “nucleic acid molecule” generally refers to any ribonucleic acid or deoxyribonucleic acid, which may be unmodified or modified DNA or RNA. “Nucleic acid” includes, but is not limited to, single-stranded and double-stranded nucleic acids. As used herein, the term “nucleic acid” also includes DNA as described above, which contains one or more modified bases. Thus, DNA containing a backbone that is modified for stability or for other reasons is a “nucleic acid.” As used herein, the term “nucleic acid” encompasses chemically, enzymatically, or metabolically modified forms of nucleic acids, as well as the chemical forms of DNA properties of viruses and cells, including, for example, unicellular and complex cells.
[0075] The terms “oligonucleotide,” “polynucleotide,” “nucleotide,” or “nucleic acid” refer to molecules containing two or more, preferably more than three, and usually more than ten deoxyribonucleotides or ribonucleotides. This exact size depends on many factors, which in turn depend on the underlying function or use of the oligonucleotide. Oligonucleotides can be produced by any of the following methods, including chemosynthesis, DNA replication, reverse transcription, or a combination thereof. Typical deoxyribonucleotides for DNA are thymine, adenine, cytosine, and guanine. Typical ribonucleotides for RNA are uracil, adenine, cytosine, and guanine.
[0076] As used herein, the nucleic acid terms “locus” or “region” refer to a small region of nucleic acid, such as a gene on a chromosome, a single nucleotide, or a CpG island.
[0077] The terms "complementary" and "complementarity" refer to nucleotides (e.g., a single nucleotide) or polynucleotides (e.g., a sequence of nucleotides) that are related by base pairing rules. For example, the sequence 5'-AGT-3' is complementary to the sequence 3'-TCA-5'. Complementarity can be "partial," where only a few bases of nucleic acids are matched according to base pairing rules. Alternatively, there can be "complete" or "whole" complementarity between nucleic acids. The degree of complementarity between nucleic acid strands results in the efficiency and strength of hybridization between nucleic acid strands. This is particularly important in amplification reactions and in detection methods that rely on binding between nucleic acids.
[0078] The term “gene” refers to a nucleic acid (e.g., DNA or RNA) sequence containing the coding sequence necessary for the production of RNA, polypeptides, or their precursors. Functional polypeptides can be encoded by their full-length coding sequence or by any portion of the coding sequence, as long as the desired activity or functional property of the polypeptide (e.g., enzymatic activity, ligand binding, signaling, etc.) is preserved. When used in reference to a gene, the term “fragment” refers to a fragment of that gene. These fragments can range in size from a few nucleotides to one nucleotide smaller than the entire gene sequence. Thus, “nucleotides containing at least a portion of a gene” can include a fragment of a gene or the entire gene.
[0079] The term “gene” also includes the coding region of a structural gene and sequences (e.g., coding sequences, regulatory sequences, structural sequences, and other sequences) located adjacent to the coding region at both the 5' and 3' ends, at a distance of approximately 1 kb at either end, so that the gene corresponds to the length of the full-length mRNA. Sequences located at the 5' position of the coding region and present on mRNA are called 5' non-translated or untranslated sequences. Sequences located at the 3' side or downstream of the coding region and present on mRNA are called 3' non-translated or untranslated sequences. The term “gene” encompasses both the cDNA and genomic forms of a gene. In some organisms (e.g., eukaryotes), the genomic form or gene clone contains a coding region interrupted by non-coding sequences called “introns” or “intervening regions” or “intervening sequences.” Introns are segments of a gene that are transcribed into nuclear RNA (hnRNA), and introns may contain regulatory elements such as enhancers. Introns are not present in messenger RNA (mRNA) transcripts because they are removed from the nucleus or primary transcript or "released by splicing." mRNA functions during translation to determine the sequence or order of amino acids in nascent polypeptides.
[0080] In addition to containing introns, genomic genes may also contain sequences located at both the 5' and 3' ends of the sequences present in the RNA transcript. These sequences are referred to as “flanking” sequences or “flanking” regions (these flanking sequences are located at the 5' or 3' end of the untranslated sequences present in the mRNA transcript). The 5' flanking region may contain regulatory sequences such as promoters and enhancers that control or influence gene transcription. The 3' flanking region may contain sequences that direct transcription termination, post-transcriptional cleavage, and polyadenylation.
[0081] When referring to a gene, the term “wild-type” refers to a gene that possesses the characteristics of a gene isolated from a naturally occurring source. When referring to a gene product, the term “wild-type” refers to a gene product that possesses the characteristics of a gene product isolated from a naturally occurring source. The term “naturally occurring,” when applied to an object, refers to the fact that the object can be found in nature. For example, a polypeptide or polynucleotide sequence present in an organism (including a virus) that can be isolated from a natural source and has not been intentionally modified by human hands in a laboratory is naturally occurring. A wild-type gene is often that gene or allele, arbitrarily referred to as the “normal” or “wild-type” form of the gene, because it is the most frequently observed in a population. In contrast, when referring to a gene or gene product, the terms “modified” or “variant” refer to a gene or gene product that exhibits modifications (i.e., altered features) in sequence and / or functional characteristics compared to a wild-type gene or gene product, respectively. It should be noted that naturally occurring variants can be isolated, and these are identified by the fact that they have altered characteristics compared to a wild-type gene or gene product.
[0082] The term "allele" refers to genetic diversity, which includes, but is not limited to, variants and mutants, polymorphism loci, as well as single nucleotide polymorphism loci, frameshifts, and splice mutations. Alleles can exist naturally in a population, or they can arise during the lifetime of any particular individual in that population.
[0083] Therefore, when used in reference to nucleotide sequences, the terms “variant” and “mutant” refer to nucleic acid sequences that differ by one or more nucleotides from another, usually related, nucleotide sequence. “Variant” is the difference between two different nucleotide sequences, and generally, one sequence is one reference sequence.
[0084] "Amplification" is a special case of nucleic acid replication that possesses template specificity. It stands in contrast to non-specific template replication (e.g., template-dependent replication, but not dependent on a specific template). In this specification, template specificity is distinguished from replication fidelity (e.g., synthesis of a suitable polynucleotide sequence) and nucleotide (ribonucleotide or deoxyribonucleotide) specificity. Template specificity is frequently described in terms of "target" specificity. Target sequences are "targets" in the sense that they are required to be selected from other nucleic acids. Amplification techniques are primarily designed for this selection.
[0085] Nucleic acid amplification typically refers to the generation of multiple copies of a polynucleotide, or a portion of a polynucleotide (for example, 10 to 100 copies of a single-stranded polynucleotide molecule, which may or may not be exactly the same), starting with a small amount of polynucleotide, where the amplified product or amplicon is generally detectable. Polynucleotide amplification encompasses a variety of chemical and enzymatic processes. The generation of multiple DNA copies from one or more copies of a target or template DNA molecule during polymerase chain reaction (PCR) or ligase chain reaction (LCR; see, for example, U.S. Patent No. 5,494,810; the whole of which is incorporated herein by reference) is a form of amplification. Additional amplification types include allele-specific PCR (see, for example, U.S. Patent No. 5,639,611; the entirety of which is incorporated herein by reference), assembly PCR (see, for example, U.S. Patent No. 5,965,408; the entirety of which is incorporated herein by reference), helicase-dependent amplification (see, for example, U.S. Patent No. 7,662,594; the entirety of which is incorporated herein by reference), hot-start PCR (see, for example, U.S. Patents No. 5,773,258 and 5,338,671; the entirety of which are incorporated herein by reference, respectively), intersequence-specific PCR, reverse PCR (see, for example, Triglia, et al. (1988) Nucleic Acids Res., 16:8186; the entirety of which is incorporated herein by reference), and ligation-mediated PCR (see, for example, Guilfoyle, R. et al., Nucleic Acids Research, 25:1854-1858 (1997); see U.S. Patent No. 5,508,169; each of these is incorporated herein by reference in whole), methylation-specific PCR (see, for example, Herman, et al., (1996) PNAS 93(13) 9821-9826; each of these is incorporated herein by reference in whole), miniprimer PCR, multiple ligation-dependent probe amplification (see, for example, Schouten, et al.See (2002) Nucleic Acids Research 30(12):e57; the whole is incorporated herein by reference), multiplex PCR (e.g., Chamberlain, et al., (1988) Nucleic Acids Research 16(23) 11141-11156; Ballabio, et al., (1990) Human Genetics 84(6) 571-573; Hayden, et al., (2008) BMC Genetics 9:80; each of these is incorporated herein by reference in its entirety), nested PCR, overlap extension PCR (e.g., Higuchi, et al., (1988) Nucleic Acids Research 16(15) 7351-7367; the whole is incorporated herein by reference), real-time PCR (e.g., Higuchi, et al. This includes, but is not limited to, methods such as: al., (1992) Biotechnology 10:413-417; Higuchi, et al., (1993) Biotechnology 11:1026-1030; each of these is incorporated herein by reference in its entirety), reverse transcription PCR (see, for example, Bustin, SA (2000) J. Molecular Endocrinology 25:169-193; the entirety of which is incorporated herein by reference), solid-phase PCR, thermally asymmetric interlaced PCR, and touchdown PCR (see, for example, Don, et al., Nucleic Acids Research (1991) 19(14) 4008; Roux, K. (1994) Biotechniques 16(5) 812-814; Hecker, et al., (1996) Biotechniques 20(3) 478-485; each of these is incorporated herein by reference in its entirety). Furthermore, polynucleotide amplification can be achieved using digital PCR (e.g., Kalinina, et al., Nucleic). See Acids Research.25;1999-2004,(1997);Vogelstein and Kinzler, Proc Natl Acad Sci USA.96;9236-41,(1999);International Patent Publication No. WO05023091A2;U.S. Patent Application Publication No. 20070202525;each of these is incorporated herein by reference in whole).
[0086] The term “polymerase chain reaction” (“PCR”) refers to the methods of KBMullis, U.S. Patents 4,683,195, 4,683,202, and 4,965,188, which describe a method for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. This process of amplifying a target sequence consists of introducing a large excess of two oligonucleotide primers into a DNA mixture containing the desired target sequence, followed by thermal cycling of the precise sequence in the presence of DNA polymerase. The two primers are complementary to their respective strands of the double-stranded target sequence. To result in amplification, the mixture is denatured, after which these primers are annealed to their complementary sequences within the target molecule. After annealing, these primers are extended by polymerase, thus forming a novel complementary strand pair. The steps of denaturation, primer annealing, and polymerase extension are repeated many times (i.e., denaturation, annealing, and extension constitute one "cycle"; multiple "cycles" are possible) to obtain highly concentrated amplified segments of the desired target sequence. The length of the amplified segment of the desired target sequence is a controllable parameter, as it is determined by the relative positions of the primers relative to each other. Due to the repeated nature of the process, this method is called a "polymerase chain reaction" ("PCR"). Since the desired amplified segments of the target sequence become the dominant sequence (in terms of concentration) in the mixture, they are called "PCR amplified" and are referred to as "PCR products" or "amplicons".
[0087] Template specificity is achieved in most amplification techniques by enzyme selection. Amplifying enzymes are those that, under the conditions in which they are used, process only the specific sequence of nucleic acids in a heterogeneous mixture of nucleic acids. For example, in the case of Q beta-replicase, MDV-1 RNA is the specific template for the replicase (Kacian et al., Proc. Natl. Acad. Sci. USA, 69:3038
[1972] ). This amplifying enzyme does not replicate other nucleic acids. Similarly, in the case of T7 RNA polymerase, this amplifying enzyme has stringent specificity for its own promoter (Chamberlin et al, Nature, 228:227
[1970] ). In the case of T4 DNA ligase, this enzyme does not ligate two oligonucleotides or polynucleotides, and there is a mismatch at the ligation junction between the oligonucleotide or polynucleotide substrate and the template (Wu and Wallace (1989) Genomics 4:560). Ultimately, it was found that thermostable template-dependent DNA polymerases (e.g., Taq and Pfu DNA polymerases) exhibit high specificity for sequences delimited by primers due to their ability to function at high temperatures, and that high temperatures create thermodynamic conditions that favor primer hybridization containing target sequences but not hybridization containing non-target sequences (HAErlich (ed.), PCR Technology, Stockton Press
[1989] ).
[0088] As used herein, the term “nucleic acid detection assay” refers to any method for determining the nucleotide composition of a nucleic acid of interest. Nucleic acid detection assays include DNA sequencing methods, probe hybridization methods, and structure-specific cleavage assays (e.g., INVADER assay, Hologic, Inc.), such as U.S. Patents No. 5,846,717, 5,985,557, 5,994,069, 6,001,567, 6,090,543, and 6,872,816; Lyamichev et al. As described in al., Nat. Biotech., 17:292 (1999), Hall et al., PNAS, USA, 97:8272 (2000), and US2009 / 0253142, each of these is incorporated herein by reference in whole for all purposes); Enzyme mismatch cleavage methods (e.g., Variagenics, U.S. Patents 6,110,684, 5,958,692, and 5,851,770, all of which are incorporated herein by reference); Polymerase chain reactions; Branched hybridization methods (e.g., Chiron, U.S. Patents 5,849,481, 5,710,264, 5,124,246, and 5,624,802, all of which are incorporated herein by reference); Rolling circle replication (e.g., U.S. Patent No. 6,210,884) , No. 6,183,960, and No. 6,235,502, all of which are incorporated herein by reference); NASBA (e.g., U.S. Patent No. 5,409,818, all of which are incorporated herein by reference), molecular beacon technique (e.g., U.S. Patent No. 6,150,097, all of which are incorporated herein by reference), E-sensor technique (Motorola, U.S. Patents No. 6,248,229, No. 6,221,583, No. 6,013,170, and No. 6,063,573, all of which are incorporated herein by reference); cycling probe technique (e.g., U.S. Patents No. 5,403,711, No. 5,011,769, and No. 5,660,988, all of which are incorporated herein by reference); Dade This includes, but is not limited to, Behring signal amplification methods (e.g., U.S. Patents 6,121,001, 6,110,677, 5,914,230, 5,882,867, and 5,792,614, all of which are incorporated herein by reference); ligase chain reactions (e.g., Barnay Proc. Natl. Acad. Sci USA 88, 189-93 (1991)); and sandwich hybridization methods (e.g., U.S. Patent 5,288,609, all of which are incorporated herein by reference).
[0089] The term "amplifiable nucleic acid" refers to nucleic acids that can be amplified by any amplification method. It is generally assumed that "amplifiable nucleic acid" includes a "sample template."
[0090] The term "sample template" refers to nucleic acids originating from the sample being analyzed for the presence of the "target" (defined below). In contrast, "background template" is used in relation to nucleic acids other than the sample template, which may or may not be present in the sample. Background templates are often largely accidental. They may be the result of carryover, or they may be due to the presence of nucleic acid contaminants that need to be separated from the sample and purified. For example, nucleic acids from organisms other than those being detected may be present as background in the test sample.
[0091] The term "primer" refers to an oligonucleotide that, whether naturally occurring during purified restriction digestion or synthetically produced, can act as a starting point for synthesis when placed under conditions that induce the synthesis of a primer extension product complementary to the nucleic acid chain (e.g., at appropriate temperature and pH in the presence of a nucleotide and an inducer such as DNA polymerase). The primer is preferably single-stranded for maximum efficiency in amplification, but can be double-stranded instead. In the case of double-stranded primers, they are first treated to separate their strands before being used to prepare the extension product. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be long enough to stimulate the synthesis of the extension product in the presence of an inducer. The exact length of the primer depends on many factors, including temperature, primer source, and method used.
[0092] The term “probe” refers to an oligonucleotide (e.g., a sequence of nucleotides) that can hybridize to another oligonucleotide of interest, whether naturally occurring during purified restriction digestion or purified synthetically, recombinantly, or by PCR amplification. Probes can be single-stranded or double-stranded. Probes are useful for the detection, identification, and isolation of specific gene sequences (e.g., “capture probes”). Since any probe used in the present invention can be labeled by any “reporter molecule” in some embodiments, it is intended to be detectable in any detection system, including but not limited to enzymes (e.g., ELISA and enzyme-based histochemical assays), fluorescence, radioactivity, and luminescence systems. The present invention is not intended to be limited to any particular detection system or label.
[0093] As used herein, “methylation” refers to methylation of cytosine at the C5 or N4 position, adenine at the N6 position, or cytosine in other types of nucleic acid methylation. In vitro amplified DNA is typically not methylated because typical in vitro DNA amplification methods do not preserve the methylation pattern of the amplified template. However, “unmethylated DNA” or “methylated DNA” can also refer to amplified DNA whose original template was unmethylated or methylated, respectively.
[0094] As a result, as used herein, “methylated nucleotide” or “methylated nucleotide base” refers to the presence of a methyl moiety on a nucleotide base, which is not present in the recognized typical nucleotide base. For example, cytosine does not contain a methyl moiety on its pyrimidine ring, but 5-methylcytosine does contain a methyl moiety at position 5 of its pyrimidine ring. Therefore, cytosine is not a methylated nucleotide, while 5-methylcytosine is a methylated nucleotide. In another example, thymine contains a methyl moiety at position 5 of its pyrimidine ring, but for the purposes of this specification, thymine is not considered a methylated nucleotide when present in DNA because thymine is a typical nucleotide base of DNA.
[0095] As used herein, “methylated nucleic acid molecule” refers to a nucleic acid molecule containing one or more methylated nucleotides.
[0096] As used herein, “methylation status,” “methylation profile,” and “methylation state” of a nucleic acid molecule refer to the presence or absence of one or more methylated nucleotide bases in the nucleic acid molecule. For example, a nucleic acid molecule containing methylated cytosine is considered methylated (for example, the methylation status of the nucleic acid molecule is methylated). A nucleic acid molecule that does not contain any methylated nucleotides is considered unmethylated.
[0097] The methylation status of a particular nucleic acid sequence (e.g., a gene marker or DNA region as described herein) can indicate the methylation status of all bases in the sequence, or the methylation status of a subset of these bases (e.g., one or more cytosines) in the sequence, or provide information about the methylation density of a region in the sequence, with or without providing precise information about the location in the sequence where methylation occurs.
[0098] The methylation status of a nucleotide locus in a nucleic acid molecule refers to the presence or absence of a methylated nucleotide at a particular locus within the nucleic acid molecule. For example, the methylation status of cytosine at the seventh nucleotide in a nucleic acid molecule is methylated when the nucleotide present at the seventh nucleotide is 5-methylcytosine. Similarly, the methylation status of cytosine at the seventh nucleotide in a nucleic acid molecule is unmethylated when the nucleotide present at the seventh nucleotide is cytosine (and not 5-methylcytosine).
[0099] The methylation status can optionally be expressed or indicated by a "methylation value" (e.g., representing methylation frequency, fraction, proportion, percentage, etc.). The methylation value can be obtained, for example, by quantifying the amount of intact nucleic acid present after restriction digestion with methylation-dependent restriction enzymes, by comparing amplification profiles after bisulfite reactions, or by comparing the sequences of bisulfite-treated nucleic acids with those of untreated nucleic acids. As a result, the value, e.g., the methylation value, can be used as a quantitative indicator of methylation status across multiple copies of a gene locus, representing the methylation status. This is a particular application when it is desirable to compare the methylation status of sequences in a sample to a threshold or reference value.
[0100] As used herein, “methylation frequency” or “methylation percentage (%)” refers to the number of cases in which a molecule or locus is methylated compared to the number of cases in which the molecule or locus is not methylated.
[0101] Thus, methylation state describes the methylation status of nucleic acids (e.g., genome sequences). In addition, methylation state refers to the characteristics of nucleic acid segments at specific genomic loci associated with methylation. These characteristics include, but are not limited to, whether any of the cytosine (C) residues in this DNA sequence are methylated, the location of the methylated C residue(s), the frequency or percentage of methylated C throughout any particular region of the nucleic acid, and allele differences in methylation, such as differences in allele origin. The terms “methylation state,” “methylation profile,” and “methylation status” also refer to relative concentrations, absolute concentrations, or patterns of methylated or unmethylated C throughout any particular region of nucleic acid in a biological sample. For example, if cytosine (C) residues in a nucleic acid sequence are methylated, it may be said to have “hypermethylated” or “increased methylation,” while if cytosine (C) residues in a DNA sequence are not methylated, it may be said to have “hypomethylated” or “decreased methylation.” Similarly, if cytosine (C) residues in a nucleic acid sequence are methylated compared to another nucleic acid sequence (e.g., from a different region or from a different individual), that sequence is considered to have hypermethylated or increased methylation compared to the other nucleic acid sequence. Alternatively, if cytosine (C) residues in a DNA sequence are not methylated compared to another nucleic acid sequence (e.g., from a different region or from a different individual), that sequence is considered to have hypomethylated or decreased methylation compared to the other nucleic acid sequence. In addition, as used herein, the term “methylation pattern” refers to aggregates of methylated and unmethylated nucleotides across a nucleic acid region.Two nucleic acids may have the same or similar methylation frequency or methylation percentage, but may have different methylation patterns when the number of methylated and unmethylated nucleotides is the same or similar throughout the region, but the positions of the methylated and unmethylated nucleotides are different. Sequences are said to have “variable methylation,” “differences in methylation,” or “different methylation states” when they differ in the degree (e.g., one has increased or decreased methylation compared to the other) or frequency of methylation. The term “variable methylation” refers to the difference in the level or pattern of nucleic acid methylation in a cancer-positive sample compared to the level or pattern of nucleic acid methylation in a cancer-negative sample. It can also refer to the difference in berels or patterns between patients with cancer recurrence after surgery and those without recurrence. Variable methylation, and specific levels or patterns of DNA methylation, are prognostic and predictive biomarkers, for example, when defining precise cutoffs or predictive properties.
[0102] The frequency of methylation states can be used to describe a single population of multiple individuals or a single sample from a single individual. For example, a nucleotide locus with a 50% methylation state frequency is methylated in 50% of instances and unmethylated in 50% of instances. Such frequencies can be used to describe, for example, the extent to which a nucleotide locus or nucleic acid region is methylated in an individual population or nucleic acid aggregate. Thus, when the methylation in a first population or pool of nucleic acid molecules differs from that in a second population or pool of nucleic acid molecules, the frequency of methylation states in the first population or pool will differ from that in the second population or pool. Such frequencies can also be used to describe, for example, the extent to which a nucleotide locus or nucleic acid region is methylated in a single individual. For example, such frequencies can be used to describe the extent to which a population of cells from a tissue sample is methylated or unmethylated at a nucleotide locus or nucleic acid region.
[0103] As used herein, "nucleotide locus" refers to the position of a nucleotide within a nucleic acid molecule. A nucleotide locus for a methylated nucleotide refers to the position of a methylated nucleotide within a nucleic acid molecule.
[0104] Typically, methylation of human DNA occurs on dinucleotide sequences (also called CpG dinucleotide sequences) containing cytosine and adjacent guanine and cytosine at the 5' position of guanine. Most cytosines within CpG dinucleotides are methylated in the human genome, but some remain unmethylated in genomic regions rich in specific CpG dinucleotides, known as CpG islands (e.g., Antequera). See et al. (1990) Cell 62: 503-514.
[0105] As used herein, “CpG island” refers to a G:C-rich region of genomic DNA containing an increased number of CpG dinucleotides compared to the whole genomic DNA. A CpG island can be at least 100, 200, or more base pairs in length, where the G:C content of this region is at least 50%, and the ratio of the observed CpG frequency to the expected frequency is 0.6. In some examples, a CpG island can be at least 500 base pairs in length, where the G:C content of this region is at least 55%, and the ratio of the observed CpG frequency to the expected frequency is 0.65. The ratio of the observed CpG frequency to the expected frequency can be calculated according to the method provided in Gardiner-Garden et al (1987) J.Mol.Biol.196:261-281. For example, the observed CpG frequency relative to the expected frequency can be calculated according to the formula R = (A × B) / (C × D), where R is the ratio of the observed CpG frequency to the expected frequency, A is the number of CpG dinucleotides in the analyzed sequence, B is the total number of nucleotides in the analyzed sequence, C is the total number of C nucleotides in the analyzed sequence, and D is the total number of G nucleotides in the analyzed sequence. The methylation state is typically determined within CpG islands, for example, in promoter regions. This can be understood through the tendency of other sequences in the human genome to undergo DNA methylation such as CpA and CpT (see Ramsahoye (2000) Proc. Natl. Acad. Sci. USA 97:5237-5242; Salmon and Kaye (1970) Biochim. Biophys. Acta. 204:340-351; Grafstrom (1985) Nucleic Acids Res. 13:2827-2842; Nyce (1986) Nucleic Acids Res. 14:4353-4367; Woodcock (1987) Biochem. Biophys. Res. Commun. 145:888-894).
[0106] As used herein, a reagent that modifies the nucleotides of a nucleic acid molecule as a function of the methylation state of the nucleic acid molecule, or a methylation-specific reagent, refers to a compound or composition, or other agent capable of altering the nucleotide sequence of a nucleic acid molecule in a manner that reflects the methylation state of the nucleic acid molecule. A method of treating a nucleic acid molecule with such a reagent may comprise contacting the nucleic acid molecule with the reagent and, if necessary, may be coupled with additional steps to achieve a desired alteration of the nucleotide sequence. Such alterations in the nucleotide sequence of a nucleic acid molecule may result in a nucleic acid molecule in which each methylated nucleotide is modified to a different nucleotide. Such alterations in the nucleotide sequence of a nucleic acid may result in a nucleic acid molecule in which each unmethylated nucleotide is modified to a different nucleotide. Such alterations in the nucleotide sequence of a nucleic acid may result in a nucleic acid molecule in which each of the selected unmethylated nucleotides (e.g., each of the unmethylated cytosines) is modified to a different nucleotide. The use of such a reagent that alters the nucleotide sequence of a nucleic acid may result in a nucleic acid molecule in which each methylated nucleotide (e.g., each of the methylated cytosines) is modified to a different nucleotide. As used herein, the use of a reagent that modifies a selected nucleotide refers to a reagent that modifies one of the four typically present nucleotides in a nucleic acid molecule (C, G, T, and A for DNA, and C, G, U, and A for RNA) such that the reagent modifies one nucleotide without modifying the other three. In one exemplary embodiment, such a reagent modifies an unmethylated selected nucleotide to produce a different nucleotide. In another exemplary embodiment, such a reagent can deaminate an unmethylated cytosine nucleotide. An exemplary reagent is a bisulfite.
[0107] As used herein, the term “bisulfite reagent” refers in some embodiments to a reagent comprising bisulfite, disulfite, hydrogen sulfite, or a combination thereof, distinguishing between methylated and unmethylated cytidine, for example, in a CpG dinucleotide sequence.
[0108] The term "methylation assay" refers to any assay used to determine the methylation status of one or more CpG dinucleotide sequences within a nucleic acid sequence.
[0109] The term "MS AP-PCR" (methylation-sensitive arbitrary-primer polymerase chain reaction) refers to a recognized scientific technique in the art that enables a global scan of the genome using CG-rich primers to focus on regions most likely to contain CpG dinucleotides, as described in Gonzalgo et al. (1997) Cancer Research 57:594-599.
[0110] The term "MethyLight (trademark)" refers to a fluorescence-based real-time PCR technique recognized in the art, as described in Eads et al. (1999) Cancer Res. 59:2302-2306.
[0111] The term "HeavyMethyl™" refers to an assay in which a methylation-specific inhibitor probe (also referred to herein as an inhibitor) that covers or is covered by the amplification primers the CpG positions between the amplification primers enables methylation-specific selective amplification of a nucleic acid sample.
[0112] The term "HeavyMethyl®MethyLight® assay" refers to a variant of the MethyLight® assay, in which the MethyLight® assay is combined with a methylation-specific inhibitory probe that covers the CpG positions between amplification primers.
[0113] The term "Ms-SNuPE" (methylation-sensitive single-nucleotide primer extension) refers to an assay recognized in the art, as described in Gonzalgo & Jones (1997) Nucleic Acids Res. 25:2529-2531.
[0114] The term "MSP" (methylation-specific PCR) refers to the methylation assays recognized in the art, as described in Herman et al. (1996) Proc. Natl. Acad. Sci. USA 93:9821-9826 and U.S. Patent No. 5,786,146.
[0115] The term "COBRA" (combined bisulfite restriction analysis) refers to the methylation assay recognized in the art, as described in Xiong & Laird (1997) Nucleic Acids Res. 25:2532-2534.
[0116] The term "MCA" (methylated CpG island amplification) refers to the methylation assay described in Toyota et al. (1999) Cancer Res. 59:2307-12 and WO00 / 26401A1.
[0117] As used herein, “selected nucleotide” refers to one of the four nucleotides typically present in a nucleic acid molecule (C, G, T, and A for DNA, and C, G, U, and A for RNA), and may include methylated derivatives of typical nucleotides (for example, if C is the selected nucleotide, both methylated and unmethylated C are included in the meaning of selected nucleotide), however, “methylated selected nucleotide” specifically refers to the methylated typical nucleotide, and “unmethylated selected nucleotide” specifically refers to the unmethylated typical nucleotide.
[0118] The terms "methylation-specific restriction enzyme" or "methylation-sensitive restriction enzyme" refer to enzymes that selectively digest nucleic acids depending on the methylation status of their recognition site. In cases of restriction enzymes that specifically cleave when the recognition site is unmethylated or hemimethylated, this cleavage is performed or not performed with significantly reduced efficiency when the recognition site is methylated. Preferably, the enzyme is a methylation-specific restriction enzyme, the recognition sequence of which contains a CG dinucleotide (e.g., a recognition sequence such as CGCG or CCCGGG). More preferably in some embodiments, the restriction enzyme does not cleave when the cytosine in this dinucleotide is methylated at carbon atom C5.
[0119] As used herein, “different nucleotides” refers to nucleotides that are chemically different from a selected nucleotide, such that a typically existing nucleotide that is complementary to the selected nucleotide is not identical to a typically existing nucleotide that is complementary to a different nucleotide, due to the different nucleotides having different Watson-Crick base pair properties than a typically selected nucleotide. For example, when C is the selected nucleotide, U or T can be different nucleotides, as illustrated by the complementarity of C to G and U or T to A. As used herein, nucleotides that are complementary to a selected nucleotide or complementary to a different nucleotide refer to nucleotides containing the selected nucleotide or a different nucleotide that, under high stringency conditions, have a higher affinity for the base pairs of the complementary nucleotides containing three of the four typically existing nucleotides. Examples of complementarity are Watson-Crick base pairs in DNA (e.g., AT and CG) and RNA (e.g., AU and CG). Therefore, for example, under high stringency conditions, the G base pair has a higher affinity for C than the G base pair for G, A, or T, so when C is the selected nucleotide, G is the nucleotide complementary to the selected nucleotide.
[0120] As used herein, the “sensitivity” of a given marker refers to the percentage of samples that report DNA methylation values above a threshold that distinguishes neoplastic from non-neoplastic samples. In some embodiments, a positive result is defined as a histologically confirmed neoplasm reporting a DNA methylation value above a threshold (e.g., a disease-associated range), and a false negative result is defined as a histologically confirmed neoplasm reporting a DNA methylation value below a threshold (e.g., a non-disease-associated range). Thus, the sensitivity value indicates the probability that a DNA methylation measurement for a given marker obtained from a known affected tissue sample falls within the range of disease-associated measurements. As defined herein, the clinical relevance of the calculated sensitivity value represents an estimate of the probability of detecting the presence of a clinical condition when a given marker is applied to a subject having that clinical condition.
[0121] As used herein, the “specificity” of a given marker refers to the percentage of non-neoplastic samples that report DNA methylation values below a threshold that distinguishes neoplastic from non-neoplastic samples. In some embodiments, a negative result is defined as a histologically confirmed non-neoplastic sample that reports DNA methylation values below a threshold (e.g., a range associated with non-disease), and a false positive result is defined as a histologically confirmed non-neoplastic sample that reports DNA methylation values above a threshold (e.g., a range associated with disease). Thus, the specificity value indicates the probability that a DNA methylation measurement for a given marker obtained from a known non-neoplastic sample falls within the range of non-disease-related measurements. As defined herein, the clinical relevance of the calculated specificity value represents an estimate of the probability of detecting the absence of a clinical condition when a given marker is applied to a subject that does not have that clinical condition.
[0122] As used herein, the term "AUC" is an abbreviation for "Area under the curve." In particular, it refers to the area under the receiver operational characteristic (ROC) curve. The ROC curve is a plot of the true positive rate against the false positive rate for different possible cutpoints of a diagnostic test. The selected cutpoints show a trade-off between sensitivity and specificity (an increase in either sensitivity is accompanied by a decrease in specificity). The area under the ROC curve (AUC) is a measure of the accuracy of a diagnostic test (a larger area is better; the optimal value is 1; a randomized trial has an ROC curve on the diagonal with an area of 0.5; see JPEgan. (1975) Signal Detection Theory and ROC Analysis, Academic Press, New York).
[0123] As used herein, the term “neoplasm” means “an abnormal tissue mass, the growth of which this abnormal tissue mass exceeds the growth of normal tissue and is discoordinate with the growth of these normal tissues.” For example, Willis RA, “The Spread of Tumors in See "The Human Body," London, Butterworth & Co., 1952.
[0124] As used herein, the term “adenoma” refers to a benign tumor of glandular origin. These growths are benign, but over time they may progress and become malignant.
[0125] The terms “precancerous” or “preneoplastic” and their equivalents refer to any cell proliferation disorder that is undergoing malignant transformation.
[0126] The "location" of neoplasms, adenomas, cancers, etc., refers to the tissue, organ, cell type, anatomical region, or body part within the subject where the neoplasm, adenoma, cancer, etc., is located.
[0127] As used herein, the application of a “diagnostic” test comprises the detection or identification of a disease state or condition in a subject, determining the likelihood that the subject will have a given disease or condition, determining the likelihood that a subject with a disease or condition will respond to treatment, determining the prognosis (or likelihood of progression or regression) of a subject with a disease or condition, and determining the effectiveness of treatment for a subject with a disease or condition. For example, a diagnosis can be used to detect the presence or likelihood of a subject having a neoplasm, or the likelihood that such a subject will respond well to a compound (e.g., a pharmaceutical, e.g., a drug) or other treatment.
[0128] As used herein, the term "marker" refers to a substance (e.g., a nucleic acid or nucleic acid region) that can be used to diagnose cancer by distinguishing cancer cells from normal cells, for example, based on their methylation status.
[0129] The term “isolated,” when used in relation to nucleic acids, such as “isolated oligonucleotide,” refers to a nucleic acid sequence that is identified and isolated from at least one contaminant nucleic acid that is typically associated with its natural source. Isolated nucleic acids exist in a form or context different from the form or context in which they are found in nature. In contrast, unisolated nucleic acids, such as DNA and RNA, are found in the form or context in which they are found in nature. Examples of unisolated nucleic acids include a given DNA sequence (e.g., a gene) found on a host cell chromosome in close proximity to adjacent genes; and RNA sequences, such as a specific mRNA sequence encoding a specific protein, found in a cell as a mixture containing multiple other mRNAs encoding numerous proteins. However, isolated nucleic acids encoding a specific protein include, for example, nucleic acids in cells that normally express the protein, where the nucleic acid is in a different chromosomal location than that of a natural cell, or otherwise adjacent to a nucleic acid sequence that is different from the form or context in which it is found in nature. Isolated nucleic acids or oligonucleotides can exist in single-stranded or double-stranded form. When isolated nucleic acids or oligonucleotides are used to express proteins, these oligonucleotides may contain a minimum sense or coding strand (i.e., oligonucleotides can be single-stranded), but may also contain both sense and antisense strands (i.e., oligonucleotides can be double-stranded). Isolated nucleic acids can be combined with other nucleic acids or molecules after isolation from their natural or typical environment. For example, isolated nucleic acids can be present in host cells where they are placed, for example, for heterologous expression.
[0130] The term “purified” refers to either a nucleic acid sequence or an amino acid sequence molecule that is removed, isolated, or separated from its natural environment. Thus, “isolated nucleic acid sequence” can be a purified nucleic acid sequence. A “substantially purified” molecule is one from which at least 60%, preferably at least 75%, and more preferably at least 90%, of the other components to which they are naturally associated. As used herein, the terms “purified” or “purify” also refer to the removal of contaminants from a sample. Removal of contaminating proteins results in an increase in the percentage of the target polypeptide or nucleic acid in the sample. In another example, recombinant polypeptides are expressed in plant, bacterial, yeast, or mammalian host cells, and the percentage of recombinant polypeptides in a sample is increased by purifying these polypeptides by removing host cell proteins.
[0131] The term "composition comprising a given polynucleotide sequence or polypeptide" broadly refers to any composition comprising a given polynucleotide sequence or polypeptide. This composition may include aqueous solutions containing salts (e.g., NaCl), surfactants (e.g., SDS), and other components (e.g., Denhart's solution, dried milk, salmon sperm DNA, etc.).
[0132] The term “sample” is used in its broadest sense. In one sense, it can refer to animal cells or tissues. In another sense, it means specimens or cultures obtained from any source, as well as biological and environmental samples. Biological samples are obtained from plants or animals (including humans) and may include fluids, solids, tissues, and gases. In some embodiments, the sample is a plasma sample. In some embodiments, the sample is a prostate tissue sample. In some embodiments, the sample is a fecal sample. Environmental samples include environmental materials such as surface materials, soil, water, and industrial samples. These examples should not be construed as limiting the types of samples that apply to the present invention.
[0133] As used herein, “remote sample” as used in some contexts refers to a sample taken indirectly from a site that is not the source of the sample of cells, tissue, or organ. For example, when evaluating sample material originating from the pancreas in a fecal sample (e.g., not from a sample taken directly from the prostate), this sample is a remote sample.
[0134] As used herein, the terms “patient” or “subject” refer to the organism that is the subject of the various tests provided by this scientific technology. The term “subject” includes animals, preferably mammals, including humans. In a preferred embodiment, the subject is a primate. In a more preferred embodiment, the subject is a human.
[0135] As used herein, the term “kit” refers to any delivery system for delivering materials. In the context of reaction assays, such delivery systems include systems that enable the storage, transport, or delivery of reaction reagents (e.g., oligonucleotides, enzymes, etc., in appropriate containers) and / or supporting materials (e.g., buffers, written instructions for performing the assay, etc.) from one place to another. For example, a kit includes one or more enclosed containers (e.g., boxes) that contain the relevant reaction reagents and / or supporting materials. As used herein, the term “fragmentation kit” refers to a delivery system comprising two or more separate containers, each containing a secondary portion of the entire kit components. The containers can be delivered together or separately to intended recipients. For example, the first container may contain an enzyme for use in an assay, while the second container may contain an oligonucleotide. The term “fragmentation kit” is intended to include, but is not limited to, kits containing analyte-specific reagents (ASRs) as defined in Section 520(e) of the Federal Food, Drug, and Cosmetic Act. In fact, any delivery system comprising two or more separate containers, each containing a sub-part of the entire kit components, falls under the term “fragmentation kit.” On the other hand, a “composite kit” refers to a delivery system containing all components of a reaction assay in a single container (for example, in a single box containing each of the desired components). The term “kit” includes both fragmentation and composite kits. Embodied technology Provided herein are scientific and technical aspects of prostate cancer screening, including, but not exclusively, methods, compositions, and related applications for detecting the presence of prostate cancer.
[0136] Indeed, as described in Examples I-VI, experiments conducted during the process of identifying embodiments of the present invention identified a novel set of 73 variable methylation regions (DMRs) to distinguish cancer from non-neoplastic control DNA and prostate-derived DNA. In addition, 10 novel DMRs were identified that are methylated in prostate epithelium (cancerous and normal) but not in normal leukocyte DNA samples. Both sets of these regions were identified from next-generation sequencing studies of CpG, enriched with tumor and normal DNA converted to bisulfite. Tumor samples included low-grade Gleason 6 and high-grade Gleason 7+ patterns. DMRs were selected using proprietary filtering and analytical pipelines and validated in independent tissue sample sets using novel methylation-specific PCR (MSP) assays. These 73 biomarker assays demonstrated excellent detection in tissue and possessed broad clinical specificity (some for cancers across many different organ sites, others specific only to prostate cancer).
[0137] These experiments list and describe 120 novel DNA methylation markers (Table 1) that distinguish prostate cancer from benign prostate tissue. From these 120 novel DNA methylation markers, further experiments identified 73 markers that can distinguish high-grade prostate cancer tissue (e.g., Gleason score 7+) from benign prostate tissue. More specifically, we identified markers and / or marker panels (e.g., chromosomal regions with annotations selected from ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1.61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047) that could distinguish prostate cancer tissue from benign prostate tissue (see Examples I-VI).
[0138] Additional experiments conducted during the development of embodiments of the present invention have shown that markers capable of distinguishing prostate cancer tissue from benign prostate tissue (e.g., SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425, MAX.chr3.193, MAX.chr2.971_3164, MAX.chr3.727_8028, HES5_0840, TPM4_8037) can be used. The goal was to identify chromosomal regions with annotations selected from SLCO3A1_6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487, which allowed us to distinguish prostate cancer tissue from benign prostate tissue (Example VIII; see Table 11).
[0139] Additional experiments conducted during the development of embodiments of the present invention focused on identifying markers (e.g., chromosomal regions with annotations selected from SERPINB9_3479, GRASP_0932, SLCO3A1_6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487) that can distinguish high-grade prostate cancer tissue (e.g., Gleason score 7+) from low-grade prostate cancer tissue (e.g., Gleason score 6), and were able to distinguish prostate cancer tissue from benign prostate tissue (Example VIII; see Table 11).
[0140] Additional experiments conducted during the development of embodiments of the present invention focused on identifying markers that can detect the presence or absence of prostate cancer in blood samples (e.g., blood plasma samples). In fact, it was possible to identify markers, and / or marker panels (e.g., chromosomal regions with annotations selected from max.chr3.193, HES5, SLCO3A1, and TPM4_8047) to detect the presence or absence of prostate cancer tissue in blood plasma samples (see Examples I-VI).
[0141] While this disclosure in this specification refers to several illustrated embodiments, understand that these embodiments are presented for illustrative purposes only and not for limitation.
[0142] In certain embodiments, the scientific and technological aspects of the present invention provide compositions and methods for identifying, determining, and / or classifying cancers such as prostate cancer. These methods comprise determining the methylation status of at least one methylation marker in a biological sample isolated from a subject (e.g., a fecal sample, a prostate tissue sample, a plasma sample), where a change in the methylation status of the marker indicates the presence, classification, or location of prostate cancer. Certain embodiments relate to markers comprising variable methylation regions (DMRs, e.g., DMR1-140, see Tables 1 and 13) used for the diagnosis (e.g., screening) of prostate cancer.
[0143] In addition to embodiments for analyzing methylation analysis of at least one marker, a region of a marker, or a base of a marker, including DMRs (e.g., DMRs 1-140) provided herein and listed in Table 1 or 3, this technology also provides a panel of markers containing at least one marker, a region of a marker, or a base of a marker, including DMRs that are useful for detecting cancer, particularly prostate cancer.
[0144] Some embodiments of this scientific technology are based on the analysis of the CpG methylation status of at least one marker, a region of the marker, or a base of the marker, including DMR.
[0145] In some embodiments, the scientific techniques of the present invention provide the use of a bisulfite technique in combination with one or more methylation assays, which determine the methylation status of CpG dinucleotide sequences in at least one marker, including DMRs (e.g., DMR1-140, see Tables 1 and 13). Genomic CpG dinucleotides can be methylated or unmethylated (alternatively also known as increased methylation and decreased methylation, respectively). However, these methods of the present invention are suitable for the analysis of heterogeneous biological samples, such as low concentrations of tumor cells or biological materials derived therefrom, in the background of a distant sample (e.g., blood, organ effluent, or feces). Consequently, when analyzing the methylation status of CpG locations in such samples, some may use quantitative assays to determine the level of methylation (e.g., percentage, fraction, proportion, ratio, or degree) at a particular CpG location.
[0146] According to the scientific technology of the present invention, determining the methylation status of CpG dinucleotide sequences in markers containing DMRs is useful for both the diagnosis and characterization of cancers such as prostate cancer. combination of markers In some embodiments, this technology relates to evaluating the methylation status of marker combinations including DMRs (DMR numbers 1-140) from Table 1, Table 3, or Table 13. In some embodiments, evaluating the methylation status of more than one marker increases the specificity and / or sensitivity of a screen or diagnosis for identifying neoplasms (e.g., prostate cancer) in a subject.
[0147] Various cancers are predicted by different combinations of markers, for example, by statistical methods related to the specificity and sensitivity of predictions. This technology provides methods for identifying predictive combinations and validated predictive combinations for several cancers. Method for assaying methylation status The most frequently used method for analyzing nucleic acids for the presence of 5-methylcytosine is based on the bisulfite method described by Frommer, et al. (Frommer et al. (1992) Proc. Natl. Acad. Sci. USA 89:1827-31, the entire work expressly incorporated herein by reference for all purposes) for the detection of 5-methylcytosine, or its diversity, in DNA. The bisulfite method for mapping 5-methylcytosine is based on the knowledge that cytosine, not 5-methylcytosine, reacts with ions of hydrogen sulfite (also known as bisulfite). This reaction is usually carried out according to the following steps: First, cytosine reacts with bisulfite to form sulfonated cytosine. Next, spontaneous deamination of the sulfonation reaction intermediate results in sulfonated uracil. Finally, this sulfonated uracil is desulfonated under alkaline conditions to form uracil. Uracil forms a base pair containing adenine, while 5-methylcytosine forms a base pair containing guanine (and therefore behaves like cytosine), making detection possible. This allows for the differentiation between unmethylated and methylated cytosine by methods such as bisulfite genome sequencing (Grigg G, & Clark S, Bioessays (1994) 16:431-36; Grigg G, DNA Seq. (1996) 6:189-98) or methylation-specific PCR (MSP), as disclosed in U.S. Patent No. 5,786,146.
[0148] Some conventional scientific techniques involve encapsulating the DNA to be analyzed in an agarose matrix, thereby preventing DNA diffusion and regeneration (bisulfite reacts only with single-stranded DNA), and replacing the precipitation and purification steps with rapid dialysis (Olek A, et al. (1996) “A modified and improved method for bisulfite based cytosine methylation analysis” Nucleic Acids Res. 24:5064-6). Therefore, it is possible to analyze the methylation status of individual cells and explain the usefulness and sensitivity of this method. An overview of conventional methods for detecting 5-methylcytosine is provided by Rein, T., et al. (1998) Nucleic Acids Res. 26:2255.
[0149] The bisulfite technique typically involves analyzing individual cytosine positions by assaying either a sequencing product (Olek & Walter (1997) Nat. Genet. 17:275-6) or a primer extension reaction (Gonzalgo & Jones (1997) Nucleic Acids Res. 25:2529-31; WO95 / 00669; U.S. Patent No. 6,251,594) following bisulfite treatment. Some methods utilize enzymatic digestion (Xiong & Laird (1997) Nucleic Acids Res. 25:2532-4). Detection by hybridization has also been described in the art (Olek et al., WO99 / 28498). In addition, the use of bisulfite techniques for methylation detection of individual genes has been described (Grigg & Clark (1994) Bioessays 16:431-6; Zeschnigk et al. (1997) Hum Mol Genet. 6:387-95; Feil et al. (1994) Nucleic Acids Res. 22:695; Martin et al. (1995) Gene 157:261-4; WO9746705; WO9515373).
[0150] Various methylation assay techniques are known in the art and can be used in conjunction with bisulfite treatment according to the scientific techniques of the present invention. These assays allow for the determination of the methylation status of one or more CpG dinucleotides (e.g., CpG islands) within a nucleic acid sequence. Such assays involve, among other techniques, sequencing of bisulfite-treated nucleic acids, PCR (for sequence-specific amplification), Southern blotting, and the use of methylation-sensitive restriction enzymes.
[0151] For example, genome sequencing has been simplified for the analysis of methylation patterns and 5-methylcytosine distribution by using bisulfite treatment (Frommer et al. (1992) Proc. Natl. Acad. Sci. USA 89:1827-1831). In addition, restriction enzyme digestion of PCR products amplified from bisulfite-converted DNA finds applications in assessing methylation status, such as described by Sadri & Hornsby (1997) Nucleic Acids Res. 24:5058-5059, or embodied in methods known as COBRA (combined bisulfite restriction analysis) (Xiong & Laird (1997) Nucleic Acids Res. 25:2532-2534).
[0152] COBRA® analysis is a useful quantitative methylation assay for determining DNA methylation levels at specific loci in small amounts of genomic DNA (Xiong & Laird, Nucleic Acids Res. 25:2532-2534, 1997). Briefly, it uses restriction enzyme digestion to reveal methylation-dependent sequence differences in PCR products of DNA treated with sodium bisulfite. These methylation-dependent sequence differences are initially introduced into the genomic DNA by standard bisulfite treatment according to the method described by Frommer et al. (Proc. Natl. Acad. Sci. USA 89:1827-1831, 1992). PCR amplification of the bisulfite-converted DNA is then performed using primers specific to the target CpG island, followed by restriction endonuclease digestion, gel electrophoresis, and detection using a specifically labeled hybridization probe. In a linearly quantitative manner across a wide range of DNA methylation levels, the relative amounts of digested and undigested PCR products represent the methylation level in the original DNA sample. Furthermore, this method can be reliably applied to DNA obtained from micro-dissected, paraffin-embedded tissue samples.
[0153] Typical reagents for COBRA® analysis (for example, those found in a typical COBRA®-based kit) may include, but are not limited to, PCR primers for specific loci (e.g., specific genes, markers, DMRs, gene regions, marker regions, bisulfite-treated DNA sequences, CpG islands, etc.); restriction enzymes and appropriate buffers; gene hybridization oligonucleotides; control hybridization oligonucleotides; kinase labeling kits for oligonucleotide probes; and labeled nucleotides. In addition, bisulfite conversion reagents may include DNA denaturation buffers; sulfonation buffers; DNA recovery reagents or kits (e.g., precipitation, ultrafiltration, affinity columns); desulfonation buffers; and DNA recovery components.
[0154] Preferably, assays such as "MethyLight®" (fluorescence-based real-time PCR technique) (Eads et al., Cancer Res. 59:2302-2306, 1999), Ms-SNuPE® (methylation-sensitive single-nucleotide primer expression) reaction (Gonzalgo & Jones, Nucleic Acids Res. 25:2529-2531, 1997), methylation-specific PCR ("MSP"; Herman et al., Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996; U.S. Patent No. 5,786,146), and methylated CpG island amplification ("MCA"; Toyota et al., Cancer Res. 59:2307-12, 1999) are used alone or in combination with one or more of these methods.
[0155] The "HeavyMethyl®" assay and technique is a quantitative method for evaluating methylation differences based on methylation-specific amplification of bisulfite-treated DNA. Methylation-specific inhibitory probes ("inhibitors") that cover the CpG positions between amplification primers, or that are covered by the amplification primers, enable methylation-specific selective amplification of nucleic acid samples.
[0156] The term "HeavyMethyl® MethyLight® assay" refers to the HeavyMethyl® MethyLight® assay, a variation of the MethyLight® assay, in which the MethyLight® assay is combined with a methylation-specific inhibitory probe that covers the CpG positions between amplification primers. The HeavyMethyl® assay can also be used in combination with methylation-specific amplification primers.
[0157] Typical reagents for HeavyMethyl® analysis (for example, those found in a typical MethyLight®-based kit) may include, but are not limited to, PCR primers for specific loci (e.g., specific genes, markers, DMRs, gene regions, marker regions, bisulfite-treated DNA sequences, CpG islands, or bisulfite-treated DNA sequences or CpG islands); inhibitory oligonucleotides; optimized PCR buffers and deoxynucleotides; and Taq polymerase.
[0158] Methylation-specific PCR (MSP) allows for the assessment of the methylation status of substantially any group of CpG sites within a CpG island, independently of the use of methylation-sensitive restriction enzymes (Herman et al. Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996; U.S. Patents 5,786,146). In short, DNA is modified with sodium bisulfite, which converts unmethylated cytosine to uracil rather than methylated cytosine, and these products are then amplified by primers specific to methylated versus unmethylated DNA. MSP requires only a small amount of DNA, is sensitive to 0.1% of methylated alleles of a given CpG island locus, and can be performed on DNA extracted from paraffin-embedded samples. Typical reagents for MSP analysis (e.g., those found in typical MSP-based kits) may include, but are not limited to, methylated and unmethylated PCR primers for specific loci (e.g., specific genes, markers, DMRs, gene regions, marker regions, bisulfite-treated DNA sequences, CpG islands, etc.); optimized PCR buffers and deoxyribonucleotides; and specificity probes.
[0159] The MethyLight® assay is a high-throughput quantitative methylation assay that utilizes fluorescence-based real-time PCR (e.g., TaqMan®) and requires no further manipulation after the PCR step (Eads et al., Cancer Res. 59:2302-2306, 1999). In short, the MethyLight® process begins with a mixed sample of genomic DNA converted into a mixed pool of methylation-dependent sequence differences in a sodium bisulfite reaction according to standard procedures (the bisulfite process converts unmethylated cytosine residues to uracil). Fluorescence-based PCR is then performed in a “biased” reaction using PCR primers that overlap, for example, known CpG dinucleotides. Sequence discrimination occurs at both the amplification and fluorescence detection levels.
[0160] The MethyLight® assay is used as a quantitative test for methylation patterns in nucleic acid samples, such as genomic DNA, where sequence discrimination occurs at the level of probe hybridization. In the quantitative version, the PCR reaction provides methylation-specific amplification in the presence of a fluorescent probe overlapping specific putative methylation sites. An unbiased control relative to the amount of input DNA is provided by a reaction in which neither primers nor probes cover any CpG dinucleotides. Alternatively, quantitative testing for genomic methylation can be achieved by exploring a biased PCR pool with either a control oligonucleotide that does not cover known methylation sites (e.g., HeavyMethyl® and fluorescence-based versions of the MSP technique) or an oligonucleotide that covers potential methylation sites.
[0161] The MethyLight® process is used with any suitable probe (e.g., TaqMan® probe, Lightcycler® probe, etc.). For example, in some applications, double-stranded genomic DNA is treated with sodium bisulfite and undergoes one of two sets of PCR reactions using TaqMan® probes and / or HeavyMethyl inhibitor oligonucleotides and TaqMan® probes, for example, with MSP primers. The TaqMan® probe is double-labeled with fluorescent "reporter" and "quencher" molecules and designed to be specific to regions with relatively high GC content, so that it melts during the PCR cycle at about 10°C, a higher temperature than the forward or reverse primers. This makes it possible to keep the TaqMan® probe completely hybridized during the PCR annealing / extension step. If Taq polymerase enzymatically synthesizes a new strand during PCR, it ultimately reaches the annealed TaqMan® probe. Next, the endonuclease activity of Taq polymerase 5' to 3' is replaced by digesting the TaqMan® probe, and a fluorescent reporter molecule is released using a real-time fluorescence detection system for quantitative detection of the unquenched signal.
[0162] Typical reagents for MethyLight® analysis (for example, those found in a typical MethyLight®-based kit) may include, but are not limited to, PCR primers for specific loci (e.g., specific genes, markers, DMRs, gene regions, marker regions, bisulfite-treated DNA sequences, CpG islands, etc.); TaqMan® or Lightcycler® probes; optimized PCR buffers and deoxyribonucleotides; and Taq polymerase.
[0163] The QM (Quantitative Methylation) assay is an alternative quantitative test for methylation patterns in genomic DNA samples, in which sequence discrimination occurs at the level of probe hybridization. In this quantitative version, the PCR reaction provides unbiased amplification in the presence of a fluorescent probe overlapping specific putative methylation sites. An unbiased control relative to the amount of input DNA is provided by a reaction in which neither primers nor probes cover any CpG dinucleotides. Alternatively, quantitative testing for genomic methylation can be achieved by exploring a biased PCR pool with either a control oligonucleotide that does not cover known methylation sites (HeavyMethyl® and fluorescence-based versions of the MSP technique) or an oligonucleotide that covers potential methylation sites.
[0164] The QM® process can be used in the amplification process with any suitable probe, such as a "TaqMan®" probe or a Lightcycler® probe. For example, double-stranded genomic DNA is treated with sodium bisulfite and then receives unbiased primers and a TaqMan® probe. The TaqMan® probe is double-labeled with fluorescent "reporter" and "quencher" molecules and designed to be specific to regions with relatively high GC content, so that it melts during the PCR cycle at a temperature of about 10°C, higher than the forward or reverse primers. This makes it possible to keep the TaqMan® probe completely hybridized during the PCR annealing / extension step. When the Taq polymerase enzymatically synthesizes a new strand during PCR, it ultimately reaches the annealed TaqMan® probe. Next, the endonuclease activity of Taq polymerase 5' to 3' displaces the TaqMan® probe by digesting it, and here, for quantitative detection of the unquenched signal, a real-time fluorescence detection system is used to release a fluorescent reporter molecule. Typical reagents for QM® analysis (e.g., as can be found in a typical QM®-based kit) may include, but are not limited to, PCR primers for specific loci (e.g., specific genes, markers, DMRs, gene regions, marker regions, bisulfite-treated DNA sequences, CpG islands, etc.); TaqMan® or Lightcycler® probes; optimized PCR buffer and deoxyribonucleotides; and Taq polymerase.
[0165] The Ms-SNuPE™ technique is a quantitative method that evaluates differences in methylation at specific CpG sites based on bisulfite treatment of DNA, followed by single-nucleotide primer extension (Gonzalgo & Jones, Nucleic Acids Res. 25:2529-2531, 1997). In short, genomic DNA is reacted with sodium bisulfite without altering 5-methylcytosine, converting unmethylated cytosine to uracil. Next, PCR primers specific to the bisulfite-converted DNA are used to amplify the desired target sequence. The resulting product is isolated and used as a template for methylation analysis at the target CpG site. This method allows for the analysis of small amounts of DNA (e.g., microscopically dissected pathological thin sections) and avoids the use of restriction enzymes to determine the methylation status at CpG sites.
[0166] Typical reagents for Ms-SNuPE® analysis (for example, those found in a typical Ms-SNuPE®-based kit) may include, but are not limited to, PCR primers for specific loci (e.g., specific genes, markers, DMRs, gene regions, marker regions, bisulfite-treated DNA sequences, CpG islands, etc.); optimized PCR buffers and deoxyribonucleotides; gel extraction kits; positive control primers; Ms-SNuPE® primers for specific loci; reaction buffers (for Ms-SNuPE reactions); and labeled nucleotides. In addition, bisulfite conversion reagents may include DNA denaturation buffers; sulfonation buffers; DNA recovery reagents or kits (e.g., precipitation, ultrafiltration, affinity columns); desulfonation buffers; and DNA recovery components.
[0167] Reduced Representation Bisulfite Sequencing (RRBS) begins with bisulfite treatment of nucleic acids, converting all unmethylated cytosines to uracil, followed by restriction enzyme digestion (e.g., by an enzyme that recognizes sites containing CG sequences, such as MspI), coupling to an adapter ligand, and then completing the sequencing of fragments. Restriction enzyme selection enriches fragments for CpG-density regions and reduces the number of redundant sequences that can be mapped to multiple gene locations during analysis. As such, RRBS reduces the complexity of nucleic acid samples by selecting one subset of restriction fragments for sequencing (e.g., by size selection using preparation gel electrophoresis). In contrast to whole-genome bisulfite sequencing, all fragments produced by restriction enzyme digestion contain DNA methylation information for at least one CpG dinucleotide. As such, RRBS enriches samples for promoters, CpG islands, and other genomic features containing high-frequency restriction enzyme cleavage sites within these regions, thus providing an assay for evaluating the methylation status of one or more genomic loci.
[0168] A typical protocol for RRBS includes the steps of digesting the nucleic acid sample with restriction enzymes such as MspI, filling the overhangs and A-tailings, ligating the adapters, converting to bisulfite, and PCR. See, for example, et al. (2005) "Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution" Nat Methods 7:133-6; Meissner et al. (2005) "Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis" Nucleic Acids Res. 33:5868-77.
[0169] In several embodiments, methylation status is evaluated using a quantitative allele-specific real-time target and signal amplification (QuARTS) assay. Three reactions occur sequentially in each QuARTS assay, comprising amplification (reaction 1) and target probe cleavage (reaction 2) in the first reaction, and FRET cleavage and fluorescence signal generation (reaction 3) in the second reaction. When the target nucleic acid is amplified by a specific primer, a specific detection probe containing a flap sequence loosely binds to the amplicon. The presence of a specific invasive oligonucleotide at the target binding site causes the flap sequence to be released into the cribase by cleavage between the detection probe and the flap sequence. The flap sequence is complementary to the non-hairpin portion of the corresponding FRET cassette. As a result, the flap sequence functions as an invasive oligonucleotide on this FRET cassette, resulting in cleavage between the FRET cassette fluorophore and the quencher, generating a fluorescence signal. This cleavage reaction cleaves multiple probes per target, making it possible to release multiple fluorophores per flap and provide exponential signal amplification. QuARTS can detect multiple targets in a single reaction well by using FRET cassettes containing different dyes. See, for example, Zou et al. (2010) “Sensitive quantification of methylated markers with a novel methylation specific technology” Clin Chem 56:A199; U.S. Patent Applications Nos. 12 / 946,737, 12 / 946,745, 12 / 946,752, and 61 / 548,639.
[0170] The term “bisulfite reagent” refers to reagents comprising bisulfite, disulfite, hydrogen sulfite, or combinations thereof, which are useful, as disclosed herein, for distinguishing between methylated and unmethylated CpG dinucleotide sequences. Methods of this treatment are known in the art (e.g., PCT / EP2004 / 011715, the entire text of which is incorporated by reference). It is preferable, but not limited to, to carry out the bisulfite treatment in the presence of a denaturing solvent such as n-alkylene glycol or diethylene glycol dimethyl ether (DME), or in the presence of dioxane or a dioxane derivative. In some embodiments, the denaturing solvent is used at a concentration between 1% and 35% (v / v). In some embodiments, the bisulfite reaction is carried out in the presence of a scavenger, not limited to chroman derivatives, e.g., 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, or trihydroxybenzone acid and its derivatives, e.g., gallic acid (see PCT / EP2004 / 011715, the whole of which is incorporated by reference). The bisulfite conversion is preferably carried out at a reaction temperature between 30°C and 70°C, where this temperature rises to over 85°C in a short period of time during the reaction (see PCT / EP2004 / 011715, the whole of which is incorporated by reference). Before quantification, the bisulfite-treated DNA is preferably purified. This can be done by any means known in the art, not limited to ultrafiltration, e.g., by means of a Microcon® column (manufactured by Millipore®). This purification is carried out in accordance with the modified manufacturer's protocol (see, for example, PCT / EP2004 / 011715, which is incorporated by reference in its entirety).
[0171] In some embodiments, the treated DNA fragments are amplified using a set of primer oligonucleotides according to the present invention (see, for example, Tables 3 and / or 5) and an amplification enzyme. Amplification of several DNA segments can be carried out simultaneously in one and the same reaction vessel. Typically, amplification is performed using polymerase chain reaction (PCR). The amplicons are generally 100 to 2000 base pairs long.
[0172] In another embodiment of this method, the use of methylation-specific primer oligonucleotides allows for the detection of the methylation status of CpG positions in or near markers containing DMRs (e.g., DMR1-140, as provided in Tables 1 and 13). This technique (MSP) is described in Herman's U.S. Patent No. 6,265,171. The use of methylation-specific primers for amplification of bisulfite-treated DNA allows for differentiation between methylated and unmethylated nucleic acids. An MSP primer pair comprises at least one primer that hybridizes to a bisulfite-treated CpG dinucleotide. Thus, the sequences of these primers contain at least one CpG dinucleotide. An MSP primer specific to unmethylated DNA contains a "T" at the C position in the CpG.
[0173] These fragments obtained by amplification can carry detectable labels, either directly or indirectly. In some embodiments, these labels are fluorescent labels, radionuclides, or desorbable molecular fragments having typical masses that can be detected in a mass spectrometer. When these labels are mass labels, some embodiments provide that the labeled amplicon has a single positive or negative active charge, enabling better detectability in a mass spectrometer. For example, this detection can be performed and visualized by matrix-assisted laser desorption / ionization mass spectrometry (MALDI) or electron spray mass spectrometry (ESI).
[0174] Methods for isolating DNA suitable for these assay scientific techniques are known in the art. In particular, some embodiments involve the isolation of nucleic acids, such as that described in U.S. Patent Application No. 13 / 470,251, “Isolation of Nucleic Acids,” which is incorporated herein by reference in whole. method In some embodiments of this technology, the following steps are taken: 1) The steps of contacting nucleic acids obtained from a subject (e.g., genomic DNA isolated from bodily fluids such as fecal samples, prostate tissue, or plasma samples) with at least one reagent or set of reagents that distinguishes methylated CpG dinucleotides from unmethylated CpG dinucleotides in at least one marker containing a DMR (e.g., DMR1-140, as provided in Tables 1 and 13), and 2) A step to detect prostate cancer (for example, provided by a sensitivity of 80% or higher and a specificity of 80% or higher), This provides a method that includes this.
[0175] In some embodiments of this technology, the following steps are taken: 1)ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1. 61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPI The steps include contacting nucleic acids obtained from a subject (e.g., genomic DNA isolated from bodily fluids such as fecal samples or prostate tissue) with at least one reagent, or a set of reagents, that distinguishes between methylated and unmethylated CpG dinucleotides within at least one marker selected from a chromosomal region having annotations selected from the group consisting of NB9_3389, SLC4A11, and TPM4_8047, and 2) A step to detect prostate cancer (for example, provided by a sensitivity of 80% or higher and a specificity of 80% or higher), This provides a method that includes this.
[0176] In some embodiments of this technology, the following steps are taken: 1)SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425, MAX.chr3.193, MAX.chr2.971_3164, M AX.chr3.727_8028, HES5_0840, TPM4_8037, SLCO3A1_6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALN The steps include contacting nucleic acids obtained from a subject (e.g., genomic DNA isolated from bodily fluids such as fecal samples or prostate tissue) with at least one reagent, or a set of reagents, which distinguishes methylated and unmethylated CpG dinucleotides within at least one marker selected from a chromosomal region having annotations selected from the group consisting of AC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487, and 2) A step to detect prostate cancer (for example, provided by a sensitivity of 80% or higher and a specificity of 80% or higher), This provides a method that includes this.
[0177] In some embodiments of this technology, the following steps are taken: 1) A step of contacting nucleic acids obtained from a subject (e.g., genomic DNA isolated from a plasma sample) with at least one reagent, or a set of reagents, that distinguishes methylated CpG dinucleotides from unmethylated CpG dinucleotides within at least one marker selected from a chromosomal region having annotations selected from the group consisting of max.chr3.193, HES5, SLCO3A1, and TPM4_8047, and 2) A step to detect prostate cancer (for example, provided by a sensitivity of 80% or higher and a specificity of 80% or higher), This provides a method that includes this.
[0178] Preferably, the sensitivity is about 70% to about 100%, or about 80% to about 90%, or about 80% to about 85%. Preferably, the specificity is about 70% to about 100%, or about 80% to about 90%, or about 80% to about 85%.
[0179] Genomic DNA can be isolated by any means, including the use of commercially available kits. In short, the biological sample in which the DNA of interest is encapsulated by a cell membrane must be disrupted and lysed by enzymatic, chemical, or mechanical means. The DNA solution can then be decontaminated with proteins and other impurities, for example, by digestion with proteinase K. The genomic DNA is then recovered from this solution. This can be carried out by a variety of methods, including salting out, organic extraction, or binding of the DNA to a solid support. The choice of method is influenced by several factors, including time, cost, and the amount of DNA required. All types of clinical samples, including neoplastic or pre-neoplastic materials, such as cell lines, tissue slides, histological biopsies, paraffin-embedded tissues, body fluids, feces, prostatic tissue, colonic effluent, urine, plasma, serum, whole blood, isolated blood cells, cells isolated from blood, and combinations thereof, are suitable for use in the methods of the present invention.
[0180] This scientific technique is not limited to the methods used to prepare samples and provide nucleic acids for testing. For example, in some embodiments, DNA is isolated from fecal, blood, or plasma samples using direct gene capture, as detailed, for example, in U.S. Patent Application No. 61 / 485386 or related methods.
[0181] Next, the genomic DNA sample is treated with at least one reagent, or a set of reagents, that distinguishes methylated and unmethylated CpG dinucleotides within at least one marker, including DMRs (e.g., DMR1-140, as provided in Tables 1 and 13).
[0182] In some embodiments, the reagent converts an unmethylated cytosine base at the 5' position to uracil, thymine, or another base that differs from cytosine in terms of hybridization behavior. However, in some embodiments, the reagent can be a methylation-sensitive restriction enzyme.
[0183] In some embodiments, genomic DNA samples are treated in such a way that the cytosine base that is not methylated at the 5' position is converted to uracil, thymine, or another base that differs from cytosine in terms of hybridization behavior. In some embodiments, this treatment is carried out with bisulfite (hydrogen sulfite, disulfite) followed by alkaline hydrolysis.
[0184] Next, the treated nucleic acids are analyzed to determine the methylation status of the target gene sequence (DMR, for example, at least one gene, genome sequence, or nucleotide from a marker containing at least one DMR selected from DMR1 to 140, as provided in Tables 1 and 13). The analytical method can be selected from those known in the art, including the analytical methods listed herein, for example, Quarts and MSP as described herein.
[0185] Abnormal methylation, more specifically hypermethylation of markers including DMRs (e.g., DMR1-140, as provided in Tables 1 and 13), is associated with prostate cancer.
[0186] This technology relates to the analysis of any sample associated with prostate cancer. For example, in some embodiments, the sample includes tissue and / or biological fluids obtained from a patient. In some embodiments, the sample includes secretions. In some embodiments, the sample includes blood, serum, plasma, gastric secretions, pancreatic juice, gastrointestinal tissue biopsy samples, cells microdissected from prostate tissue biopsy, and / or prostate cells recovered from feces. In some embodiments, the subject is human. The sample may include cells, secretions, or tissues from the prostate, liver, bile ducts, pancreas, stomach, colon, rectum, esophagus, small intestine, appendix, duodenum, polyps, gallbladder, anus, and / or peritoneum. In some embodiments, the sample includes cellular fluid, ascites, urine, feces, pancreatic juice, fluids obtained during endoscopy, blood, mucus, or saliva. In some embodiments, the sample is a fecal sample.
[0187] Such samples can be obtained by any number of means known in the art, as will be apparent to those skilled in the art. For example, urine and fecal samples are readily obtainable, while blood, ascites, serum, or pancreatic fluid samples can be obtained parenterally, for example, by using needles and syringes. Cell-free samples, or substantially cell-free samples, can be obtained by subjecting the sample to a variety of techniques known to those skilled in the art, including but not limited to centrifugation and filtration. While it is generally preferred to obtain samples using non-invasive techniques, it is still preferable to obtain samples such as tissue homogenates, tissue sections, and biopsy specimens.
[0188] In some embodiments, this technology relates to a method for treating a patient (for example, a patient with prostate cancer, early-stage prostate cancer, or potentially prostate cancer), the method of determining the methylation status of one or more DMRs as provided herein, and administering a treatment to the patient based on the result of determining this methylation status. This treatment may be the administration of a pharmaceutical compound, a vaccine, the performance of surgery, imaging of a patient, or the performance of another test. Preferably, this application is in methods for clinical screening, methods for prognosis assessment, methods for monitoring treatment outcomes, methods for identifying patients most likely to respond to a particular therapeutic treatment, methods for imaging patients or subjects, and methods for drug screening and development.
[0189] In some embodiments of this technology, a method for diagnosing prostate cancer in a subject is provided. As used herein, the terms “diagnosing” and “diagnosing” mean a method by which a person skilled in the art can estimate, and even determine, whether a subject is suffering from a given disease or condition, or is likely to suffer from a given disease or condition in the future. A person skilled in the art often makes a diagnosis based on one or more diagnostic indicators, such as a biomarker (e.g., a DMR as disclosed herein), the methylation status of which indicates the presence, severity, or absence of the condition.
[0190] In addition to diagnosis, clinical cancer prognosis involves determining the aggressiveness of the cancer and the likelihood of tumor recurrence, and planning the most effective treatment. Even when it is possible to perform a more accurate prognosis, or to assess the potential risk of developing cancer, it is possible to select appropriate treatment, and in some cases, treatment that is less burdensome to the patient. Evaluation of cancer biomarkers (e.g., determining methylation status) is useful for differentiating subjects from those with a good prognosis and / or those at low risk of developing cancer that do not require treatment, or those at higher risk of developing cancer, to those with limited treatment options, or those who may experience cancer recurrence and benefit from more intensive treatment.
[0191] Such actions, when used herein, “making a diagnosis” or “diagnosing,” further include determining the risk of developing cancer or determining the prognosis, which can be provided for predicting clinical outcomes (with or without medical intervention), selecting appropriate treatment (or whether treatment is effective), or monitoring current treatment and potentially changing treatment, based on measurements of diagnostic biomarkers disclosed herein (e.g., DMR). Furthermore, in some embodiments of the disclosed subject matter of the Invention, multiple determinations of biomarkers over time can be made to facilitate diagnosis and / or prognosis. Changes in biomarkers over time can be used to predict clinical regression, monitor the progression of prostate cancer, and / or monitor the effectiveness of appropriate treatments targeting cancer. In such embodiments of the example, one can expect to observe changes in the methylation status of one or more biomarkers disclosed herein (e.g., DMR) (and potentially one or more additional biomarkers if monitored) over time in a biological sample during an effective course of treatment.
[0192] The disclosed subject matter of the present invention further provides, in some embodiments, a method for determining whether to initiate or continue cancer prevention or treatment in a subject. In some embodiments, the method comprises: providing a series of biological samples from a subject over a period of time; analyzing the series of biological samples to determine the methylation status of at least one biomarker disclosed herein in each biological sample; and comparing any measurable changes in the methylation status of one or more biomarkers in each biological sample. Using any changes in the methylation status of biomarkers over a period of time, it is possible to predict the risk of developing cancer, predict clinical regression, determine whether to initiate or continue cancer prevention or treatment, and determine whether the current treatment is effectively treating the cancer. For example, the first time point may be selected before the initiation of treatment, and the second time point may be selected at some point after the initiation of treatment. It is possible to measure the methylation status in each of the samples taken from different time points and to note qualitative and / or quantitative differences. Changes in the methylation status of biomarker levels from different samples can be correlated with determining prostate cancer risk, prognosis, treatment effectiveness, and / or cancer progression in a subject.
[0193] In preferred embodiments, these methods and compositions of the present invention are for the treatment or diagnosis of a disease in its early stages, for example, before the symptoms of the disease appear. In some embodiments, these methods and compositions of the present invention are for the treatment or diagnosis of a disease in the clinical stage.
[0194] As described, in some embodiments, it is possible to make multiple determinations of one or more diagnostic or prognostic biomarkers, and to use changes in these markers over time to determine the diagnosis or prognosis. For example, a diagnostic marker can be determined initially and again a second time. In such embodiments, an increase in the marker from the first to the second measurement can be a diagnosis of a particular type or severity of cancer, or a given prognosis. Similarly, a decrease in the marker from the first to the second measurement can indicate a particular type or severity of cancer, or a given prognosis. Furthermore, the degree of change in one or more markers can be related to the severity of cancer and future adverse events. Those skilled in the art will understand that in certain embodiments, comparative measurements of the same biomarker can be made at multiple time points, and that a given biomarker can be measured at a first time point and a second biomarker at a second time point, and that the comparison of these markers can provide diagnostic information.
[0195] As used herein, the phrase “determining prognosis” refers to a method by which a person skilled in the art can predict the course or outcome of a condition in a subject. The term “prognosis” does not refer to the ability to predict the course or outcome of a condition with 100% accuracy, or even the ability that a given course or outcome is a predictable degree of probability based on the methylation status of a biomarker (e.g., DMR). Instead, a person skilled in the art will understand that the term “prognosis” refers to an increased probability that a particular course or outcome will occur in a subject exhibiting a given condition, compared to these individuals that do not exhibit this condition; that is, an increased probability that the course or outcome is more likely to occur in a subject exhibiting a given condition. For example, in an individual that does not exhibit this condition (e.g., has normal methylation status of one or more DMRs), the probability of a given outcome (e.g., suffering from prostate cancer) is very low.
[0196] In some embodiments, statistical analysis associates prognostic indicators with predisposition to adverse outcomes. For example, in some embodiments, a methylation status different from that in a normal control sample obtained from patients without cancer may indicate that a subject is more likely to suffer from cancer than a subject with a methylation status more similar to that in the control sample, as determined by the level of statistical significance. In addition, changes in methylation status from baseline (e.g., "normal") levels may reflect the subject's prognosis, and the degree of change in methylation status may be related to the severity of adverse events. Statistical significance is often determined by comparing two or more populations and determining confidence intervals and / or p-values. For example, Dowdy and Wearden, Statistics, which is incorporated herein by reference in its entirety. See *For Research*, John Wiley & Sons, New York, 1983. Exemplary confidence intervals for the subject matter of the present invention are 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9%, and 99.99%, and exemplary p-values are 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001, and 0.0001.
[0197] In other embodiments, it is possible to establish threshold values for changes in the methylation status of prognostic or diagnostic biomarkers (e.g., DMRs) disclosed herein, and to simply compare the degree of change in the methylation status of this biomarker in a biological sample with the threshold value for change in methylation status. Preferred threshold values for methylation status of biomarkers provided herein are about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 50%, about 75%, about 100%, and about 150%. In yet another embodiment, it is possible to establish a "calculation chart" by which the methylation status of a prognostic or diagnostic indicator (biomarker, or combination of biomarkers) is directly related to properties relevant to a given outcome. Those skilled in the art will be familiar with the use of such calculation charts and will understand that the uncertainty in this measurement is identical to the uncertainty in the marker concentration, as it refers to measurements of individual samples rather than population mean values, and will relate the two numerical values.
[0198] In some embodiments, biological samples are analyzed simultaneously with control samples so that results obtained from biological samples can be compared with results obtained from control samples. In addition, it is possible to provide standard curves, and it is intended that these standard curves can be compared with the assay results for the biological samples. Such standard curves present the methylation status of biomarkers as a function of assay units, for example, as a function of fluorescence signal intensity when fluorescent labels are used. Using samples taken from multiple donors, it is possible to provide standard curves for the control methylation status of one or more biomarkers in normal tissue, and standard curves for the "at risk" level of one or more biomarkers in tissue taken from donors with metaplasia or from donors with prostate cancer. In certain embodiments of this method, a subject is identified as having metaplasia based on the identification of abnormal methylation status of one or more DMRs provided herein in a biological sample obtained from the subject. In other embodiments of this method, the detection of abnormal methylation status of one or more such biomarkers in a biological sample obtained from a subject results in a subject being identified as having cancer.
[0199] It is possible to analyze additional markers within a single test sample, either separately or simultaneously. For example, several markers can be combined in a single test for efficient processing of multiple samples and potentially to provide higher diagnostic and / or prognostic accuracy. In addition, those skilled in the art will recognize the value of testing multiple samples from the same subject (e.g., at consecutive points in time). Testing such consecutive samples can allow for the identification of changes in the methylation status of markers over time. Changes in methylation status, and the absence of such changes, can provide useful information about the disease state, including, but not limited to, identifying the subject's outcome, including the approximate time since the event occurred, the presence and amount of recoverable tissue, the suitability of drug therapy, the effectiveness of various therapies, and the risk of future events.
[0200] Biomarker analysis can be performed in a variety of physical forms. For example, microtiter plates or automated applications can be used to facilitate the processing of numerous test samples. Alternatively, single-sample formats can be developed to facilitate immediate treatment and diagnosis in timely settings, such as mobile transport or emergency rooms.
[0201] In some embodiments, when a subject is diagnosed with prostate cancer, there is a measurable difference in the methylation status of at least one biomarker in the sample when compared to a control methylation status. Conversely, when no change in methylation status is identified in a biological sample, the subject can be identified as not having prostate cancer, having no risk of cancer, or having a low risk of cancer. In this regard, subjects with cancer or at risk of cancer can be distinguished from subjects who are substantially cancerous or have a low risk of cancer to substantially no cancer. These subjects at risk of developing prostate cancer can be placed in a more intensive and / or periodic screening schedule, including endoscopy. On the other hand, these subjects with a low risk to substantially no risk can avoid undergoing endoscopy until future screening, such as a screening conducted according to the scientific techniques of the present invention, which indicates that the risk of prostate cancer has manifested in these subjects.
[0202] As described above, by embodiments of the scientific and technological methods of the present invention, detecting a change in the methylation state of one or more biomarkers can be a qualitative determination, or it can be a quantitative determination. For example, a step of diagnosing a subject who has or is at risk of developing prostate cancer involves performing a certain threshold measurement, for example, showing that the methylation state of one or more biomarkers in a biological sample differs from a predetermined control methylation state. In some embodiments of this method, the control methylation state is a detectable methylation state of any of the biomarkers. In other embodiments of the method, where a control sample is tested simultaneously with a biological sample, the predetermined methylation state is the methylation state in the control sample. In other embodiments of this method, the predetermined methylation state is based on and / or identified by a standard curve. In other embodiments of this method, the predetermined methylation state is a specific state or a range of states. As such, within acceptable limits apparent to those skilled in the art, it is possible to select a predetermined methylation state, partly based on the method to be implemented and the desired specificity, etc.
[0203] Furthermore, with respect to the diagnostic method, the preferred subject is a vertebrate subject. The preferred vertebrate is a warm-blooded animal, and the preferred warm-blooded animal is a mammal. The preferred mammal is most preferably a human. As used herein, the term “subject” includes both human and animal subjects. Thus, veterinary therapeutic applications are provided herein. As such, the scientific techniques of the present invention are provided for the diagnosis of mammals such as humans, and economically important mammals such as animals raised on farms for human consumption, such as Amur tigers, which are critically endangered, and / or animals that are socially important to humans, such as animals kept as pets or in zoos. Examples of such animals include, but are not limited to, carnivores such as cats and dogs; swine, including pigs, hogs, and wild boars; ruminants and / or ungulates such as cattle, bulls, sheep, giraffes, deer, goats, bison, and camels; and horses. Therefore, also provided are the diagnosis and treatment of livestock, including but not limited to domesticated pigs, ruminants, ungulates, horses (including racehorses), and the like. The subject matter of the disclosed invention further includes a system for diagnosing prostate cancer in a subject. This system can be provided, for example, as a commercially available kit, which can be used to screen for the risk of prostate cancer or to diagnose prostate cancer in a subject from which a biological sample is taken. An exemplary system provided in accordance with the science and art of the invention comprises evaluating the methylation status of DMR, as provided in Tables 1 and 3.
[0204] The present invention can also be configured as follows.
[0205] [1] A method for characterizing samples from human patients, a) Obtaining DNA from human patient samples, b) Assay the methylation status of DNA methylation markers containing bases in variable methylation regions (DMRs) selected from the group consisting of DMRs 1 to 140 from Table 1 or 13. c) Comparing the assayed methylation status of the one or more DNA methylation markers with the methylation level criteria for the one or more DNA methylation markers in human patients without prostate cancer. The method comprising the above.
[0206] [2] The method according to [1], wherein the sample is a fecal sample, a tissue sample, a prostate tissue sample, a blood sample, a plasma sample, or a urine sample.
[0207] [3] The sample is a prostate tissue sample, and the DMR is selected from DMR numbers 63, 3, 64, 70, 7, 39, 8, 10, 11, 12, 14, 41, 81, 16, 17, 18, 20, 21, 44, 25, and 47, or The sample is a plasma sample, and the DMR is selected from DMR numbers 17, 12, 45, and 47. The method described in [1].
[0208] [4] The method according to [1], comprising assaying multiple DNA methylation markers.
[0209] [5] The method according to [1], comprising assaying 2 to 11 DNA methylation markers.
[0210] [6] The method according to [1], comprising assaying 12 to 140 DNA methylation markers.
[0211] [7] The method according to [1], wherein assaying the methylation state of one or more DNA methylation markers in the sample comprises determining the methylation state of a single base.
[0212] [8] The method according to [1], wherein assaying the methylation status of one or more DNA methylation markers in the sample comprises determining the degree of methylation at multiple bases.
[0213] [9] The method according to [1], comprising assaying the methylation state of the forward chain or assaying the methylation state of the reverse chain.
[0214]
[10] The method according to [1], wherein the DNA methylation marker is a single region of 100 or fewer bases.
[0215]
[11] The method according to [1], wherein the DNA methylation marker is a single region of 500 or fewer bases.
[0216]
[12] The method according to [1], wherein the DNA methylation marker is a single region of 1000 or fewer bases.
[0217]
[13] The method according to [1], wherein the DNA methylation marker is a single region of 5000 or fewer bases.
[0218]
[14] The method according to [1], wherein the DNA methylation marker is a single base.
[0219]
[15] The method according to [1], wherein the DNA methylation marker is located in a high CpG density promoter.
[0220]
[16] The method according to [1], wherein the assay comprises using a methylation-specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, a methylation-specific nuclease, mass-based separation, or target capture.
[0221]
[17] The method according to [1], wherein the assay comprises the use of a methylation-specific oligonucleotide selected from SEQ ID NOs: 1 to 234.
[0222]
[18] The method according to [1], wherein a chromosomal region having an annotation selected from the group consisting of ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1.61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047 contains the DNA methylation marker.
[0223]
[19] SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425, MAX .chr3.193, MAX.chr2.971_3164, MAX.chr3.727_8028, HES5_0840, TPM4_8037, SLCO3A1_6187, ITPRIPL1 The method according to [1], wherein a chromosomal region having an annotation selected from the group consisting of _1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487 contains the DNA methylation marker.
[0224]
[20] The method according to [1], wherein a chromosomal region having an annotation selected from the group consisting of max.chr3.193, HES5, SLCO3A1, and TPM4_8047 contains the DNA methylation marker.
[0225] 〔twenty one〕 A method for characterizing samples obtained from human patients, a) Determine the methylation status of the DNA methylation marker in the sample containing a base in a DMR selected from the group consisting of DMR1 to 140 from Tables 1 and 13. b) Comparing the methylation status of the DNA methylation marker from the patient sample with the methylation status of the DNA methylation marker from a normal control sample from a human subject without prostate cancer. c) Determining the confidence interval and / or p-value of the difference in methylation status between the human patient and the normal control sample. The method comprising the above.
[0226] 〔twenty two〕 The method according to
[21] , wherein the confidence interval is 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9%, or 99.99%, and the p-value is 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001, or 0.0001.
[0227] 〔twenty three〕 A method for characterizing a sample obtained from a human subject, The process involves reacting nucleic acids containing DMR with a bisulfite reagent to produce nucleic acids reacted with bisulfite. To sequence the nucleic acid reacted with the bisulfite and to provide the nucleotide sequence of the nucleic acid reacted with the bisulfite, The nucleotide sequence of the nucleic acid reacted with the bisulfite is compared with the nucleotide sequence of the nucleic acid containing the DMR from a subject without prostate cancer, and the differences between the two sequences are identified. The method comprising the above.
[0228] 〔twenty four〕 A system for characterizing samples obtained from human subjects, An analytical component configured to determine the methylation state of a sample, A software component configured to compare the methylation state of the sample with the methylation state of a control sample or reference sample recorded in a database, and A warning component configured to determine a single value based on a combination of methylation states and to warn users of prostate cancer-related methylation states. The system comprising the above.
[0229] 〔twenty five〕 The system according to
[24] , wherein the sample comprises nucleic acid containing DMR.
[0230]
[26] The system according to
[24] , further comprising a component for isolating nucleic acids.
[0231]
[27] The system according to
[24] , further comprising a component for collecting a sample.
[0232]
[28] The system according to
[24] , wherein the sample is a fecal sample, a tissue sample, a prostate tissue sample, a blood sample, a plasma sample, or a urine sample.
[0233]
[29] The system according to
[24] , wherein the database includes nucleic acid sequences containing DMRs.
[0234]
[30] The system according to
[24] , wherein the database includes nucleic acid sequences from subjects who do not have prostate cancer.
[0235]
[31] A method for screening for prostate cancer in a sample obtained from a subject, 1) Assaying the methylation status of markers in samples obtained from subjects, and 2) Identifying a subject who has prostate cancer when the methylation state of the marker differs from the methylation state of the marker assayed on a subject who does not have prostate cancer. Equipped with, The aforementioned marker contains a base in a variable methylation region (DMR) selected from the group consisting of DMR1 to 140 from Table 1 or 13. The aforementioned method.
[0236]
[32] The method according to
[31] , comprising assaying multiple markers.
[0237]
[33] The method according to
[31] , wherein assaying the methylation state of the marker in the sample comprises determining the methylation state of a single base.
[0238]
[34] The method according to
[31] , wherein assaying the methylation state of the marker in the sample comprises determining the degree of methylation at multiple bases.
[0239]
[35] The method according to
[31] , wherein the methylation state of the marker comprises increased or decreased methylation of the marker compared to the normal methylation state of the marker.
[0240]
[36] The method according to
[31] , wherein the methylation state of the marker has a different pattern of methylation of the marker compared to the normal methylation state of the marker.
[0241]
[37] The method according to
[31] , comprising assaying the methylation state of the forward chain or assaying the methylation state of the reverse chain.
[0242]
[38] The method according to
[31] , wherein the marker is a region of 100 or fewer bases.
[0243]
[39] The method according to
[31] , wherein the marker is a region of 500 or fewer bases.
[0244]
[40] The method according to
[31] , wherein the marker is a region of 1000 or fewer bases.
[0245]
[41] The method according to
[31] , wherein the marker is a region of 5000 or fewer bases.
[0246]
[42] The method described in
[31] , wherein the marker is a single base.
[0247]
[43] The method according to
[31] , wherein the marker is located in a high CpG density promoter.
[0248]
[44] The method according to
[31] , wherein the sample is a fecal sample, a tissue sample, a prostate tissue sample, a blood sample, a plasma sample, or a urine sample.
[0249]
[45] The method according to
[31] , wherein the assay comprises using a methylation-specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, a methylation-specific nuclease, mass-based separation, or target capture.
[0250]
[46] The method according to
[31] , wherein the assay comprises the use of a methylation-specific oligonucleotide selected from the group consisting of SEQ ID NOs: 1 to 234.
[0251]
[47] The method according to
[31] , wherein a chromosomal region having annotations selected from the group consisting of ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1.61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047 contains the marker.
[0252]
[48] SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425, M AX.chr3.193, MAX.chr2.971_3164, MAX.chr3.727_8028, HES5_0840, TPM4_8037, SLCO3A1_6187, ITPRI The method according to
[31] , wherein a chromosomal region having an annotation selected from the group consisting of PL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487 contains the marker.
[0253]
[49] The method according to
[31] , wherein a chromosomal region having annotations selected from the group consisting of max.chr3.193, HES5, SLCO3A1, and TPM4_8047 contains the marker.
[0254]
[50] 1) Bisulfite reagent, and 2) A control nucleic acid having a methylation status associated with subjects without prostate cancer, comprising a sequence from a DMR selected from the group consisting of DMR1 to 140 from Tables 1 and 13. A kit, comprising:
[0255] 〔51〕 A kit, comprising a bisulfite reagent and an oligonucleotide according to 〔47〕.
[0256] 〔52〕 A sample collector for obtaining a sample from a subject, A reagent for isolating nucleic acid from the sample, A bisulfite reagent, and An oligonucleotide, A kit, comprising the above in accordance with 〔47〕.
[0257] 〔53〕 The kit according to 〔52〕, wherein the sample is a stool sample, a tissue sample, a prostate tissue sample, a blood sample, a plasma sample, or a urine sample.
[0258] 〔54〕 A composition comprising a nucleic acid containing a DMR and a bisulfite reagent.
[0259] 〔55〕 A composition comprising a nucleic acid containing a DMR and an oligonucleotide according to 〔47〕.
[0260] 〔56〕 A composition comprising a nucleic acid containing a DMR and a methylation-sensitive restriction enzyme.
[0261] 〔57〕 A composition comprising a nucleic acid containing a DMR and a polymerase.
[0262] 〔58〕 A method of screening for prostate cancer in a sample obtained from a subject, comprising: a) determining the methylation state of a marker in the sample, wherein the marker comprises a base in a DMR selected from the group consisting of DMR 1 to 140 from Tables 1 and 13, b) Comparing the methylation state of the marker from the subject sample with the methylation state of the marker from a normal control sample from a subject without prostate cancer. c) Determine the confidence interval and / or p-value of the difference in methylation status between the subject sample and the normal control sample. The method comprising the above.
[0263]
[59] The method according to
[58] , wherein the confidence interval is 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9%, or 99.99%, and the p-value is 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001, or 0.0001.
[0264]
[60] A method for screening for prostate cancer in samples obtained from a subject, The process involves reacting nucleic acids containing DMR with a bisulfite reagent to produce nucleic acids reacted with bisulfite. To sequence the nucleic acid reacted with the bisulfite and to provide the nucleotide sequence of the nucleic acid reacted with the bisulfite, The nucleotide sequence of the nucleic acid reacted with the bisulfite is compared with the nucleotide sequence of the nucleic acid containing the DMR from a subject without prostate cancer, and the differences between the two sequences are identified. Identifying the subject as having prostate cancer when a difference exists, The method comprising the above.
[0265]
[61] A system for screening for prostate cancer in samples obtained from subjects, An analytical component configured to determine the methylation state of a sample, A software component configured to compare the methylation state of the sample with the methylation state of a control sample or reference sample recorded in a database, and an alert component configured to determine a single value based on the combination of methylation states and alert a user of a prostate cancer-related methylation state, the system comprising the same.
[0266] 〔62〕 The system according to 〔61〕, wherein the sample comprises a nucleic acid containing a DMR.
[0267] 〔63〕 The system according to 〔61〕, further comprising a component for isolating nucleic acids.
[0268] 〔64〕 The system according to 〔61〕, further comprising a component for collecting a sample.
[0269] 〔65〕 The system according to 〔61〕, further comprising a component for collecting a stool sample, a prostate tissue sample, a blood sample, and / or a plasma sample.
[0270] 〔66〕 The system according to 〔61〕, wherein the database comprises nucleic acid sequences containing a DMR.
[0271] 〔67〕 The system according to 〔61〕, wherein the database comprises nucleic acid sequences from a subject who does not have prostate cancer.
[0272] 〔68〕 A set of isolated nucleic acids, wherein each nucleic acid comprises a sequence containing a DMR.
[0273] 〔69〕 The set of nucleic acids according to 〔68〕, wherein each nucleic acid comprises a sequence from a subject who does not have prostate cancer.
[0274] 〔70〕 A system comprising the set of nucleic acids according to 〔68〕 or 〔69〕, and a database of nucleic acid sequences associated with the set of nucleic acids.
[0275]
[71] The system according to
[70] , further comprising a bisulfite reagent.
[0276]
[72] The system according to
[70] , further comprising a nucleic acid sequencer.
[0277]
[73] A method for characterizing a biological sample, (a) Methylation levels of CpG sites for two or more genes selected from ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1.61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047 in biological samples from human individuals. Treating the genomic DNA in the aforementioned biological sample with bisulfite, The following set of primers for the two or more genes selected above: A set of primers for ACOXL consisting of SEQ ID NOs: 93 and 94. A set of primers consisting of sequence numbers 27 and 28 for AKR1B1_3644, A set of primers for ANXA2 consisting of sequence numbers 89 and 90. A set of primers consisting of sequence numbers 85 and 86 for CHST11_2206. A set of primers consisting of sequence numbers 31 and 32 for FLJ45983. A set of primers for GAS6 consisting of sequence numbers 117 and 118. A set of primers for GRASP consisting of sequence numbers 33 and 34. A set of primers for HAPLN3 consisting of SEQ ID NOs: 37 and 38. A set of primers for HCG4P6 consisting of SEQ ID NOs: 39 and 40. A set of primers consisting of sequence numbers 41 and 42 for HES5_0822. A set of primers for ITPRIPL1 consisting of sequence numbers 45 and 46. A set of primers for KCNK4 consisting of SEQ ID NOs: 125 and 126. A set of primers consisting of sequence numbers 91 and 92 for MAX.chr1.61519554-61519667, A set of primers consisting of sequence numbers 49 and 50 for MAX.chr2.97193166-97193253, A set of primers consisting of SEQ ID NOs: 51 and 52 for MAX.chr3.193. A set of primers consisting of sequence numbers 53 and 54 for MAX.chr3.72788028-72788112, A set of primers for RAI1_7469 consisting of SEQ ID NOs: 55 and 56. A set of primers for RASSF2 consisting of SEQ ID NOs: 57 and 58. A set of primers for SERPINB9_3389, consisting of sequence numbers 129 and 130. A set of primers for SLC4A11, consisting of SEQ ID NOs: 59 and 60, and A set of primers for TPM4_8047 consisting of SEQ ID NOs: 123 and 124. Using the above, amplify the genomic DNA treated with bisulfite, and The methylation level of the CpG site is determined by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genome sequencing PCR. To measure through, (b) Comparing the methylation level with the methylation level of the corresponding set of genes in a control sample that does not have prostate cancer, (c) When the methylation levels measured in two or more genes are higher than the methylation levels measured in each of the control samples, the individual is determined to have prostate cancer. The method comprising the above.
[0278]
[74] The method according to
[73] , wherein the biological sample is a blood sample or a tissue sample.
[0279]
[75] The method according to
[74] , wherein the tissue is prostate tissue.
[0280]
[76] The method according to
[73] , wherein the CpG site is located in the coding region or the regulating region.
[0281]
[77] The method according to
[73] , wherein measuring the methylation level of a CpG site for two or more genes comprises a determination selected from the group consisting of determining the methylation score of the CpG site and determining the methylation frequency of the CpG site.
[0282]
[78] A method for characterizing a plasma sample, (a) The methylation levels of the CpG sites for two or more genes selected from max.chr3.193, HES5, SLCO3A1, and TPM4_8047 in a human plasma sample. Treating the genomic DNA in the aforementioned biological sample with bisulfite, The following set of primers for two or more selected genes: A set of primers consisting of SEQ ID NOs: 174 and 175 for max.chr3.193. A set of primers for HES5 consisting of sequence numbers 180 and 181. A set of primers for SLCO3A1 consisting of SEQ ID NOs: 171 and 172, and A set of primers for TPM4_8047 consisting of SEQ ID NOs: 189 and 190. Amplifying genomic DNA treated with the bisulfite using the above, and The methylation level of the CpG site is determined by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genome sequencing PCR. To measure through, (b) Comparing the methylation level with the methylation level of the corresponding set of genes in a control sample that does not have prostate cancer, (c) When the methylation levels measured in two or more genes are higher than the methylation levels measured in each of the control samples, the individual is determined to have prostate cancer. The method comprising the above.
[0283]
[79] The method according to
[78] , wherein the CpG site is located in the code region or the adjustment region.
[0284]
[80] The method according to
[78] , wherein measuring the methylation level of a CpG site for two or more genes comprises a determination selected from the group consisting of determining the methylation score of the CpG site and determining the methylation frequency of the CpG site.
[0285]
[81] A method for characterizing a biological sample, If the biological sample is a prostate tissue sample from the human individual, then ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1.61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047 in the human biological sample, or When the biological sample is a plasma sample from a human individual, max.chr3.193, HES5, SLCO3A1, and TPM4_8047 in the biological sample from the human individual, The methylation level of the CpG site for two or more genes selected from either of the following: Treating the genomic DNA in the aforementioned biological sample with bisulfite, Amplifying the bisulfite-treated genomic DNA using a set of primers for two or more selected genes, and The methylation level of the CpG site is determined by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genome sequencing PCR. To measure through, The method comprising the above.
[0286]
[82] The methylation level is compared with the methylation level of the corresponding set of genes in a control sample that does not have prostate cancer, and When the methylation levels measured in the two or more genes are higher than the methylation levels measured in each of the control samples, the individual is determined to have prostate cancer. The method described in
[81] further comprises the following:
[0287]
[83] If the biological sample is a tissue sample, the following set of primers for the two or more selected genes: A set of primers for ACOXL consisting of SEQ ID NOs: 93 and 94. A set of primers consisting of sequence numbers 27 and 28 for AKR1B1_3644, A set of primers for ANXA2 consisting of sequence numbers 89 and 90. A set of primers consisting of sequence numbers 85 and 86 for CHST11_2206. A set of primers consisting of sequence numbers 31 and 32 for FLJ45983. A set of primers for GAS6 consisting of sequence numbers 117 and 118. A set of primers for GRASP consisting of sequence numbers 33 and 34. A set of primers for HAPLN3 consisting of SEQ ID NOs: 37 and 38. A set of primers for HCG4P6 consisting of SEQ ID NOs: 39 and 40. A set of primers consisting of sequence numbers 41 and 42 for HES5_0822. A set of primers for ITPRIPL1 consisting of sequence numbers 45 and 46. A set of primers for KCNK4 consisting of SEQ ID NOs: 125 and 126. A set of primers consisting of sequence numbers 91 and 92 for MAX.chr1.61519554-61519667, A set of primers consisting of sequence numbers 49 and 50 for MAX.chr2.97193166-97193253, A set of primers consisting of SEQ ID NOs: 51 and 52 for MAX.chr3.193. A set of primers consisting of sequence numbers 53 and 54 for MAX.chr3.72788028-72788112, A set of primers for RAI1_7469 consisting of SEQ ID NOs: 55 and 56. A set of primers for RASSF2 consisting of SEQ ID NOs: 57 and 58. A set of primers for SERPINB9_3389, consisting of sequence numbers 129 and 130. A set of primers for SLC4A11 consisting of SEQ ID NOs: 59 and 60. A set of primers for TPM4_8047 consisting of SEQ ID NOs: 123 and 124. The method described in
[81] , using the
[0288]
[84] If the biological sample is a plasma sample, the following set of primers for the two or more selected genes: A set of primers consisting of SEQ ID NOs: 174 and 175 for max.chr3.193. A set of primers for HES5 consisting of sequence numbers 180 and 181. A set of primers for SLCO3A1 consisting of Sequence IDs 171 and 172, and A set of primers for TPM4_8047 consisting of SEQ ID NOs: 189 and 190. The method described in
[81] , using the
[0289]
[85] The method according to
[81] , wherein the tissue sample is a prostate tissue sample.
[0290]
[86] The CpG site is located in the code region or the adjustment region as described in
[81] . method.
[0291]
[87] The measurement of the methylation level of a CpG site for two or more genes comprises a determination selected from the group consisting of determining the methylation score of the CpG site and determining the methylation frequency of the CpG site, as described in
[81] . method.
[0292]
[88] A method for characterizing a biological sample, (a) SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425, MAX.chr3.193, MAX.chr2.971_3164, MAX.chr3.727_8028, HES5_0840, TPM4_8037, S in biological samples from human individuals The methylation levels of the CpG sites for two or more genes selected from LCO3A1_6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487 are determined as follows: Treating the genetic DNA in the aforementioned biological sample with bisulfite, Amplifying the bisulfite-treated genomic DNA using the following set of primers for two or more selected genes, and The methylation level of the CpG site is determined by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genome sequencing PCR. To measure through, (b) Comparing the methylation level with the methylation level of the corresponding set of genes in a control sample that does not have prostate cancer, (c) When the methylation levels measured in two or more genes are higher than the methylation levels measured in each of the control samples, the individual is determined to have prostate cancer. The method comprising the above.
[0293]
[89] The method according to
[88] , wherein the biological sample is a blood sample or a tissue sample.
[0294]
[90] The method according to
[89] , wherein the tissue is prostate tissue.
[0295]
[91] The method according to
[88] , wherein the CpG site is located in the code region or the adjustment region.
[0296]
[92] The method according to
[88] , wherein measuring the methylation level of a CpG site for two or more genes comprises a determination selected from the group consisting of determining the methylation score of the CpG site and determining the methylation frequency of the CpG site.
[0297]
[93] The set of primers for the two or more selected genes is: A set of primers consisting of sequence numbers 177 and 178 or 177 and 219 for MAX.chr3.727_8028. A set of primers consisting of sequence numbers 220 and 221 for RASGRF2_6325. A set of primers for ZNF655_6075 consisting of sequence numbers 210 and 211. A set of primers for PAMR1_7364, consisting of sequence numbers 223 and 224. A set of primers consisting of sequence numbers 216 and 217 for ST6GALNAC2_1113. A set of primers consisting of sequence numbers 229 and 230 for CCNJL_9070. A set of primers consisting of sequence numbers 213 and 214 for KCNB2_9128. A set of primers for IGFBP7_6412, consisting of sequence numbers 226 and 227. A set of primers consisting of sequence numbers 232 and 233 for WNT3A_5487. A set of primers consisting of sequence numbers 147 and 148 for SERPINB9_3479. A set of primers consisting of sequence numbers 150 and 151 for FLOT1_1665. A set of primers consisting of sequence numbers 153 and 154 for HCG4P6_4618. A set of primers consisting of sequence numbers 156 and 157 for CHST11_2206. A set of primers consisting of sequence numbers 159 and 160 for MAX.chr12.485. A set of primers consisting of sequence numbers 162 and 163 for GRASP_0932. A set of primers for GAS6_6425 consisting of sequence numbers 165 and 166. A set of primers consisting of sequence numbers 174 and 175 for MAX.chr3.193. A set of primers consisting of sequence numbers 198 and 199 for MAX.chr2.971. A set of primers consisting of sequence numbers 180 and 181 for HES5_0840. A set of primers for TPM4_8037, consisting of sequence numbers 189 and 190. A set of primers consisting of sequence numbers 171 and 172 for SLCO3A1_6187. A set of primers consisting of sequence numbers 195 and 196 for ITPRIPL1_1244, and A set of primers consisting of sequence numbers 201 and 202 for AKR1B1_3644. The method described in
[88] , selected from the above.
[0298]
[94] A method for characterizing cancerous prostate tissue, (a) The methylation levels of the CpG site for two or more genes selected from SERPINB9_3479, GRASP_0932, SLCO3A1_6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487 in biological samples from human individuals. Treating the genomic DNA in the aforementioned biological sample with bisulfite, Amplifying the bisulfite-treated genomic DNA using the following set of primers for two or more selected genes, and The methylation level of the CpG site is determined by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genome sequencing PCR. To measure through, (b) Comparing the methylation level to the methylation level of a corresponding set of genes from prostate cancer tissue having a Gleason score of 6, and (c) When the methylation levels measured in two or more genes are higher than the methylation levels measured in the corresponding set of genes from prostate cancer tissue having a Gleason score of 6, it is determined that the individual contains prostate cancer tissue having a Gleason score of 7 or higher. The method comprising the above.
[0299]
[95] The method according to
[94] , wherein the CpG site is located in the coding region or the regulating region.
[0300]
[96] The method according to
[94] , wherein measuring the methylation level of a CpG site for two or more genes comprises a determination selected from the group consisting of determining the methylation score of the CpG site and determining the methylation frequency of the CpG site.
[0301]
[97] The set of primers for the two or more selected genes is: A set of primers consisting of sequence numbers 147 and 148 for SERPINB9_3479. A set of primers consisting of sequence numbers 162 and 163 for GRASP_0932. A set of primers consisting of sequence numbers 171 and 172 for SLCO3A1_6187. A set of primers for ITPRIPL1_1244, consisting of sequence numbers 195 and 196. A set of primers consisting of sequence numbers 201 and 202 for AKR1B1_3644. A set of primers consisting of sequence numbers 220 and 221 for RASGRF2_6325. A set of primers for ZNF655_6075 consisting of sequence numbers 210 and 211. A set of primers for PAMR1_7364, consisting of sequence numbers 223 and 224. A set of primers consisting of sequence numbers 216 and 217 for ST6GALNAC2_1113. A set of primers consisting of sequence numbers 229 and 230 for CCNJL_9070. A set of primers consisting of sequence numbers 213 and 214 for KCNB2_9128. A set of primers for IGFBP7_6412 consisting of SEQ ID NOs: 226 and 227, and A set of primers consisting of sequence numbers 232 and 233 for WNT3A_5487. The method described in
[94] , selected from the above.
[0302]
[98] SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425 , MAX.chr3.193, MAX.chr2.971_3164, MAX.chr3.727_8028, HES5_0840, TPM4_8037, SLCO3A1_6187, I A method for measuring the methylation level of one or more CpG sites in genes selected from TPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487, a) Extracting genomic DNA from biological samples of human individuals suspected of having or who have prostate cancer. b) Treating the extracted genomic DNA with bisulfite, c)SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425, MAX.chr 3.193, MAX.chr2.971_3164, MAX.chr3.727_8028, HES5_0840, TPM4_8037, SLCO3A1_6187, ITPRIPL1_1244, AKR1 Amplifying genomic DNA treated with bisulfite using primers consisting of primer pairs specific to one or more CpG sites in genes selected from B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487, and d) By methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, or bisulfite genome sequencing PCR, SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425, MAX.chr3.193, MAX.chr2.971_3164, MAX.chr3.727_80 28. Measuring the methylation level of one or more CpG sites in genes selected from HES5_0840, TPM4_8037, SLCO3A1_6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487. The method comprising the above.
[0303]
[99] The method described in
[98] , wherein the sample is a prostate tissue sample.
[0304]
[100] SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GA S6_6425, MAX.chr3.193, MAX.chr2.971_3164, MAX.chr3.727_8028, HES5_0840, TPM4_8037 The primer pairs specific to SLCO3A1_6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487 are A set of primers consisting of sequence numbers 177 and 178 or 177 and 219 for MAX.chr3.727_8028. A set of primers consisting of sequence numbers 220 and 221 for RASGRF2_6325. A set of primers for ZNF655_6075 consisting of sequence numbers 210 and 211. A set of primers for PAMR1_7364, consisting of sequence numbers 223 and 224. A set of primers consisting of sequence numbers 216 and 217 for ST6GALNAC2_1113. A set of primers consisting of sequence numbers 229 and 230 for CCNJL_9070. A set of primers consisting of sequence numbers 213 and 214 for KCNB2_9128. A set of primers for IGFBP7_6412, consisting of sequence numbers 226 and 227. A set of primers consisting of sequence numbers 232 and 233 for WNT3A_5487. A set of primers consisting of sequence numbers 147 and 148 for SERPINB9_3479. A set of primers consisting of sequence numbers 150 and 151 for FLOT1_1665. A set of primers consisting of sequence numbers 153 and 154 for HCG4P6_4618. A set of primers consisting of sequence numbers 156 and 157 for CHST11_2206. A set of primers consisting of sequence numbers 159 and 160 for MAX.chr12.485. A set of primers consisting of sequence numbers 162 and 163 for GRASP_0932. A set of primers for GAS6_6425 consisting of sequence numbers 165 and 166. A set of primers consisting of sequence numbers 174 and 175 for MAX.chr3.193. A set of primers consisting of sequence numbers 198 and 199 for MAX.chr2.971. A set of primers consisting of sequence numbers 180 and 181 for HES5_0840. A set of primers for TPM4_8037, consisting of sequence numbers 189 and 190. A set of primers consisting of sequence numbers 171 and 172 for SLCO3A1_6187. A set of primers consisting of sequence numbers 195 and 196 for ITPRIPL1_1244, and A set of primers consisting of sequence numbers 201 and 202 for AKR1B1_3644. The method described in
[98] , comprising:
[0305]
[101] A method for measuring the methylation level of one or more CpG sites in genes selected from ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1.61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047, a) Extracting genomic DNA from biological samples of human individuals suspected of having or who have prostate cancer. b) Treating the extracted genomic DNA with bisulfite, c) Amplifying genomic DNA treated with bisulfite using primers consisting of primer pairs specific to one or more CpG sites in genes selected from ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLIN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1.61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047, and d) Identification of ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1 by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, or bisulfite genome sequencing PCR. Measuring the methylation level of one or more CpG sites in genes selected from 61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047, The method comprising the above.
[0306]
[102] The method described in
[101] , wherein the sample is a prostate tissue sample.
[0307]
[103] The primer pairs specific to ACOXL, AKR1B1_3644, ANXA2, CHST11_2206, FLJ45983, GAS6, GRASP, HAPLN3, HCG4P6, HES5_0822, ITPRIPL1, KCNK4, MAX.chr1.61519554-61519667, MAX.chr2.97193166-97193253, MAX.chr3.193, MAX.chr3.72788028-72788112, RAI1_7469, RASSF2, SERPINB9_3389, SLC4A11, and TPM4_8047 are A set of primers for ACOXL consisting of SEQ ID NOs: 93 and 94. A set of primers consisting of sequence numbers 27 and 28 for AKR1B1_3644, A set of primers for ANXA2 consisting of sequence numbers 89 and 90. A set of primers consisting of sequence numbers 85 and 86 for CHST11_2206. A set of primers consisting of sequence numbers 31 and 32 for FLJ45983. A set of primers for GAS6 consisting of sequence numbers 117 and 118. A set of primers for GRASP consisting of sequence numbers 33 and 34. A set of primers for HAPLN3 consisting of SEQ ID NOs: 37 and 38. A set of primers for HCG4P6 consisting of SEQ ID NOs: 39 and 40. A set of primers consisting of sequence numbers 41 and 42 for HES5_0822. A set of primers for ITPRIPL1 consisting of sequence numbers 45 and 46. A set of primers for KCNK4 consisting of SEQ ID NOs: 125 and 126. A set of primers consisting of sequence numbers 91 and 92 for MAX.chr1.61519554-61519667, A set of primers consisting of sequence numbers 49 and 50 for MAX.chr2.97193166-97193253, A set of primers consisting of SEQ ID NOs: 51 and 52 for MAX.chr3.193. A set of primers consisting of sequence numbers 53 and 54 for MAX.chr3.72788028-72788112, A set of primers for RAI1_7469 consisting of SEQ ID NOs: 55 and 56. A set of primers for RASSF2 consisting of SEQ ID NOs: 57 and 58. A set of primers for SERPINB9_3389, consisting of sequence numbers 129 and 130. A set of primers for SLC4A11 consisting of SEQ ID NOs: 59 and 60, and A set of primers for TPM4_8047 consisting of SEQ ID NOs: 123 and 124. The method described in
[101] , comprising:
[0308]
[104] A method for measuring the methylation level of one or more CpG sites in genes selected from max.chr3.193, HES5, SLCO3A1, and TPM4_8047, a) Extracting genomic DNA from plasma samples of individuals suspected of having or who have prostate cancer. b) Treating the extracted genomic DNA with bisulfite, c) Amplifying genomic DNA treated with bisulfite using primers consisting of primer pairs specific to one or more CpG sites in genes selected from max.chr3.193, HES5, SLCO3A1, and TPM4_8047, and d) Measuring the methylation level of one or more CpG sites in genes selected from max.chr3.193, HES5, SLCO3A1, and TPM4_8047 by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, or bisulfite genome sequencing PCR. The method comprising the above.
[0309]
[105] The primer pairs specific to max.chr3.193, HES5, SLCO3A1, and TPM4_8047 are A set of primers consisting of SEQ ID NOs: 174 and 175 for max.chr3.193. A set of primers for HES5 consisting of SEQ ID NOs: 180 and 181, a set of primers for SLCO3A1 consisting of SEQ ID NOs: 171 and 172, and A set of primers for TPM4_8047 consisting of SEQ ID NOs: 189 and 190. The method described in
[98] , comprising: [Examples]
[0310] Example I This example provides materials and methods for Examples II, III, IV, V, and VI.
[0311] Examples II, III, IV, V, and VI demonstrate that methylated DNA markers can distinguish prostate tissue (e.g., cancerous prostate tissue and / or non-cancerous prostate tissue) from non-prostate tissue (e.g., leukocytes), that methylated DNA markers can distinguish cancerous prostate tissue from non-cancerous prostate tissue, that methylated DNA markers can distinguish very high-grade cancerous prostate tissue (e.g., Gleason score of 7.0 or higher (e.g., 7, 8, 9, 10)) from low-grade cancerous prostate tissue (e.g., Gleason score of less than 7 (e.g., 6)), and that methylated DNA markers can detect PCa in blood samples.
[0312] These experiments involved five stages. First, Reduced Representation Bisulfite Sequencing (RRBS) (see, e.g., Gu H, et al., Nat Methods 2010;7:133-6) was used on DNA extracted from prostate cancer (PCa) tissue (both Gleason score 6 and 7+), normal prostates, and buffy coat samples from healthy volunteers to discover DNA methylation markers. Second, variable methylation regions (DMRs) were identified by strict filtration criteria, and real-time methylation-specific PCR assays (qMSP) were developed using these sequences. These assays were then applied to the original sample sets to ensure reproducibility (technical validation) of the results. Third, candidate markers were selected for best-performed biovalidation of qMSP on DNA extracted from independent archived cases and control tissues. Fourth, candidate marker sequences were compared in silico across a pan-cancer RRBS sequencing dataset, and the degree of site-specific methylation was measured for each marker. Fifth, a set of high-performance PCa markers was selected to evaluate PCa detection in clinical culture media by testing in blinded, independent plasma samples. Research subjects and samples This study was approved by the Mayo Clinic Institutional Review Board (Rochester, MN). Fresh frozen (FF) tissue, plasma, and buffy coat samples were provided by an IRB-approved patient biobank. Tumor tissue sections were re-examined by a specialist GI pathologist to confirm the diagnosis and estimate neoplastic cell solidity. These sections were then subjected to macrodissection. Genomic DNA was purified using the QiaAmp Mini kit (Qiagen, Valencia CA) and then re-purified using the AMPure XP kit (Beckman Coulter, Brea CA). Preparation of a Reduced Representation Bisulfite Sequencing Library 150 ng of DNA from each sample was diluted in 26 µl of Te buffer (5.77 ng / µl). This was digested overnight in 1 µl (20 units) of MspI in 1x final concentration CutSmart buffer (New England Biolabs). The 3' overhang was repaired, and tailing to A was induced with a mixture of 0.6 µl of 100 mM dATP, 0.06 µl of 100 mM dCTP, and 0.06 µl of dGTP, containing 2 µl (10 units) of Klenow DNA polymerase (New England Biolabs). The product was incubated at 30°C for 20 minutes, at 37°C for 20 minutes, and held at 4°C. After end repair, the product was purified by 2x Agencourt Ampure XP beads (Beckman Coulter), washed twice with 70% EtOH, and eluted in 20 µl of water. The Illumina adapter was ligated to the product using 1 µl of T4 ligase (400 units) in 1x T4 ligase buffer incubated overnight at 16°C. The product was treated at 65°C for 20 minutes to inactivate the enzyme by heat. After ligation, the product was purified by 2x Agencourt Ampure XP beads (Beckman Coulter), washed twice with 70% EtOH, and eluted in 47 µl of water. 45 µl of the product was converted with bisulfite using the EZ-96 DNA methylation kit (Zymo Research) as described in their protocol. The converted product was purified by 2x Agencourt Ampure XP beads (Beckman Coulter), washed twice with 70% EtOH, and eluted in 22 µl of water. In a total volume of 50 µl, the Illumina index was added via PCR using 16 µl of the product converted to bisulfite, 1 µl (2.5 units) of PfuTurbo Cx hotstart DNA polymerase, 0.5 µl of dNTPs (25 mM each), 6 µl of Illumina index (2.5 µM each), and 1x PfuTurbo Cx hotstart DNA polymerase buffer.The product was dual-size, selected by collecting the supernatant with Ampure XP at 0.7x elution, followed by storage of the bead-bound product with Ampure XP at 1.2x elution. The final product was eluted in 40 μl. DNA molecular weight yield was determined by Pico Green (Molecular Probes) and measured on a Tecan fluorometer. DNA size was determined on an Agilent 2100 (Agilent) using a High Sensitivity DNA chip. The molar concentration of the product was calculated, and these samples were pooled equimolarly at 4 samples / pool per 10 nM. Massively parallel sequencing and bioinformatics These samples were loaded onto flow cells according to randomized lane assignments. Sequencing was performed on Illumina HiSeq2000 using a next-generation sequencing core at the Mayo Clinic Medical Genome Facility. Reads were unidirectional for 10¹ cycles. Each flow cell lane generated 100 million to 120 million reads, which was sufficient for a median sequencing depth coverage of 30 to 50 times for aligned sequences. Standard Illumina pipeline software retrieved bases and generated reads in fastq format. SAAP-RRBS (Streamline Analysis and Annotation Pipeline for Reduced Representation Bisulfite Sequencing) was used for sequence read evaluation and cleanup, alignment to reference genome, methylation status extraction, and CpG reporting and annotation. CpGs with low coverage (≤10) were excluded. Third-order analysis consisted of excluding CpGs with no informational value or low sample coverage, identifying methylated CpG regions containing low background and high-density clusters within a sliding 100 bp window. The read depth criterion was based on the desired statistical ability to detect a 10% difference in %methylation between cases and controls. Statistical significance was determined by logistic regression of methylation percentage per DMR based on read counts. To account for variations in read depth across individual subjects, an overdispersed logistic regression model was used, where the variance parameter was estimated using Pearson's chi-squared statistic of residuals from the fitted model. DMRs were ranked according to their significance level, and further consideration was given to cases where %methylation in the control group was ≤1% and ≥10% in cancer. For most organ sites, this resulted in hundreds of possible candidates. The additional filters used were receiver operating characteristic curve (AUC), %methylation case / control ratio change (FC), and range under co-methylation between CpG-positive samples across the entire DMR (and their absence in controls). Technical and biological tissue validation Methylation-specific PCR (MSP) marker assays were developed for 120 of the most promising DMRs from the PCa discovery dataset, as determined by the criteria listed above. Primers were designed either by software (Methprimer - University of California, San Francisco, CA) or manually. These assays were rigorously tested and optimized using SYBR Green qPCR on bisulfite-converted controls (methylated and unmethylated genomic DNA), unconverted controls, and non-template controls. Assays cross-reacted with negative controls were either redesigned or discarded. In addition, melting curve analysis was performed to ensure that specific amplification occurred. For the technical validation phase, the same samples used for RRBS discovery were retested with qMSP. A β-actin assay, designed to be methylation-blinded, was used as a common factor representing the total DNA copies. This data was analyzed by logistic regression, comparing AUC and signal to the discovered values against background results. Approximately 27% of markers were below expectations and were removed. The remainder (N=72) were tested on an independent tissue sample extension set using qMSP. These results were analyzed logistically, and the outcome metrics were AUC, FC, and % methylation of robust case samples. Verification of the entire organ system To evaluate the best methylation markers performed outside the prostate, a comparative % methylation matrix of CpG was constructed using sequencing reads for validation DMRs across prostate samples, compared to other major cancers (colon, pancreas, esophagus, liver, and stomach). A final panel of markers was selected and tested in plasma based on 1) overall performance in the biovalidation phase and 2) site-specific characteristics of these markers across other cancers. To best detect PCa in blood, a robust marker panel was selected that gave an excess of non-PCa DNA and exhibited both general-purpose and prostate-specific cancer signals. QuART assay design and plasma validation DNA was extracted from 3-4 mL of deposited, frozen plasma using the following automated silica bead method (see, for example, U.S. Patent Application No. 15 / 335,111):
[0313] [Table 1]
[0314] Next, the DNA was converted to bisulfite and purified using the following method:
[0315] [Table 2]
[0316] Next, the sample (10 μL) was manipulated on an ABI real-time PCR instrument using primers and probes developed from DMR sequences in QuARTs-X format (see, for example, U.S. Patent Application No. 15 / 335,096). Plasmids containing the target marker sequence were obtained from Genscript and diluted to a nominal concentration of 1 copy per 15 μL reaction in 1X QuART reagent. This reaction mixture was distributed to each of 96 wells and circulated for 45 cycles on a LightCycler, and data were collected. Each well was assigned either a sample or no sample. The Poisson random variable was set to 1, and the average success rate was entered by trial and error. These values were then used to calculate the cumulative probability for that value. When the cumulative probability was equal to the percentage of wells containing the signal, the correct average success rate, in this case the copy number, was found. These plasmids were diluted and used as assay standards.
[0317] QuARTs-X was performed by first preparing a pre-amplification plate of the sample, which was primed for up to 12 targets undergoing 11 cycles of amplification. This product was then diluted 1:9 and used as a template for the subsequent QuART reaction, which involved only three targets in a three-step reaction. The standard material used to calculate chain count was not pre-amplified. Pre-amplifying the sample, rather than the chains, increased the sensitivity of the assay.
[0318] The results were analyzed using Regression Partition (rPart). Combining multiple methylation markers into a single risk score using logistic regression is a standard technique. However, finding and / or modeling higher-order interactions between markers within a logistic model is challenging. This limits the predictive power of a panel of markers when such effects exist. Regression Partition (rPart) is a decision tree approach that makes it possible to find higher-order interactions between markers in a way that maximizes the predictive accuracy of the marker panel. Example II. This embodiment describes the RRBS results and the technical validation results.
[0319] PCa resulted in numerous discriminative dermogenic regions (DMRs), many of which had not been previously identified. By comparing methylation of normal prostate and PCa samples, 256 regions were identified that met the cutoffs of AUC > 0.85, FC > 20, and p-value < 0.05. Of these regions, 22 had an AUC of 1. When comparing PCa and normal prostate methylation to their buffy-coat samples, 1895 regions exceeded the cutoff, and 827 had a perfect AUC score. In both comparisons, FCs extended to hundreds and thousands, respectively. We explored potential DMRs that distinguished Gleason 7+ PCa (high-grade, treatment indicated cancer) versus Gleason 6 PCa (low-grade in most cases, treatment usually not required). Regarding FC > 2 (7+ / 6), with a maximum FC = 72, 129 DMRs were observed.
[0320] The second stage in the biomarker development process was to address the uncertainty arising from the relatively small sample size in the initial discovery stage. Retesting the same sample using different scientific and technological platforms on a smaller number of DMRs or marker candidates was the first step toward this objective. Real-time or quantitative methylation-specific PCR (qMSP) using SYBR Green is an easy-to-use method with high analytical sensitivity and specificity.
[0321] By increasing the cutoff until a manageable range (N=120) was obtained, the top candidate was selected from all three comparisons, and DMR was chosen (see Table 1).
[0322] [Table 3] JPEG0007949098000004.jpg229169JPEG0007949098000005.jpg238169JPEG0007949098000006.jpg239169JPEG0007949098000007.jpg62169
[0323] Furthermore, DMR sequences had to show significant co-methylation or adjacent methylation throughout the entire treated CpG, on a strand-by-strand basis. qMSP and other amplification-based methods worked best when all treated CpGs were methylated (in cases) and unmethylated (in controls). After QC testing on strands (universally methylated genomic DNA treated with bisulfite) and control samples (unmethylated genomic DNA treated with bisulfite, unconverted genomic DNA, etc.), 99 regions were performed with sufficient linearity, specificity, and robustness and used to retest Phase 1 samples. Logistically analyzed results for most assays were comparable to the % methylation derived from the sequencing stage. All DNA strands in all samples exceeded 100, with an average within the 1000s. The Z marker (see, for example, U.S. Patent Application No. 14 / 966,617) consistently showed an AUC of 1 and very high FCs compared to normal buffy-coated samples. When the cancer vs. benign ratio for the Z marker candidates was investigated, nearly half were 1:1, and the rest had a ratio between 2 and 10 (the middle Z). Of the cancer marker vs. benign markers, 34 contained an AUC in the range of 0.95 to 1. All were negative with respect to buffy-coated samples. In the Phase 1 results, markers that distinguished Gleason 7+ cancer from Gleason 6 cancer generally continued their performance in validation studies. 26 markers had a maximum of 292 FCs, exceeding 2.
[0324] Table 2 shows, for the DMRs identified in Table 1, 1) the area under the curve (AUC) for prostate cells with a Gleason score of 6 or higher versus benign prostate cells, 2) the magnification change (FC) for prostate cells with a Gleason score of 6 or higher versus benign prostate cells, and 3) the magnification change (FC) for prostate cells with a Gleason score of 6 or higher versus Buffy (standard) cells.
[0325] [Table 4] JPEG0007949098000009.jpg238169JPEG0007949098000010.jpg235169JPEG0007949098000011.jpg165169
[0326] Example III. For qMSP biovalidation on DNA extracted from independent archived cases and control tissues, the best-performing candidate markers identified through the experiments described in Example II were selected.
[0327] From the Phase 2 trial, 73 markers were selected (see Table 3) and performed on an independent set of prostate tissue (N=35 normal prostates, 19 with Gleason score 6, and 31 with Gleason score 7+) and normal buffy coat (N=36) samples. Twenty-seven markers were removed, primarily those with a sub-0.85 AUC in the cancer vs. benign set, or those with near-complete positive methylation in the Z marker set. Most of the Gleason 7+ vs. Gleason 6 markers were carried over. All samples were assayed by qMSP as previously described. Table 3 lists the DMR genomic coordinates and AUCs for Gleason score 7+ prostate tissue versus normal benign prostate tissue for 73 assays, and the corresponding primer sequences are provided in Table 4.
[0328] [Table 5] JPEG0007949098000013.jpg236169JPEG0007949098000014.jpg82169
[0329] [Table 6] JPEG0007949098000016.jpg234169JPEG0007949098000017.jpg234169JPEG0007949098000018.jpg238169JPEG00079490980 00019.jpg237169JPEG0007949098000020.jpg239169JPEG0007949098000021.jpg237169JPEG0007949098000022.jpg227169
[0330] AUC was generally good, but not as good as expected in this extended independent set for earlier validation. As shown in Table 3, the 20 markers had AUC values (Gleason 7+ vs. normal prostate) in the range of 0.95–0.99 and FC17–164. % methylation in the buffy coat samples was negligible except for GRASP, which had a single outlier.
[0331] Since clinical follow-up data were available for prostate cases, it was decided to explore the prognostic morphology of candidate epigenetic markers. Five prognostic markers (FAM78A, WNT3A, GAS6, LOC100129726, and MAX.chr3.727) were selected using mathematical methods to discover and / or model higher-order interactions between markers in a logistic model, including regression partitioning (rPart). Risk grouping was defined by methylated DNA markers, which added a significant prognostic content in predicting progression-free survival compared to Gleason scoring (p<0.0001), whereas Gleason scoring did not include the additional value compared to methylated DNA marker risk grouping (p=0.2174). Example IV. Additional experiments were conducted to identify markers that can distinguish between PCa Gleason scores above 7 and Gleason scores of 6 in prostate tissue. These experiments utilized QuARTs-X (Quantitative Allele-Specific Real-Time Target and Signal Assay) (see, for example, U.S. Patent Application No. 15 / 335,096). Table 5 shows the marker sensitivity at 100% and magnification changes for PCa Gleason 7+ vs. Gleason 6 in prostate tissue (oligo sequences are provided in Table 6).
[0332] [Table 7]
[0333] [Table 8] JPEG0007949098000025.jpg215169JPEG0007949098000026.jpg232169JPEG0007949098000027.jpg74169
[0334] Example V. We conducted experiments in which candidate marker sequences were compared in silico across a pan-cancer RRBS sequencing dataset, and the degree of site-specific methylation for each marker was measured.
[0335] This study demonstrates DNA methylation signatures that accurately predict tumor location within human anatomical morphology. To better define organ-site specificity, an in silico CpGx sample matrix of RRBS was constructed, with methylation values derived for each of 73 DMRs / markers across multiple cancers and organ tissues. These included tissues from the prostate, liver, colon, pancreas, lung, esophagus, stomach, and bile duct. It was possible to model location specificity by quantitative methylation differences between organ sites and the degree of adjacent methylation across DMRs (defined by pattern recognition). As shown in Table 7, eight markers demonstrated specificity only for prostate cancer, while 11 markers were universal across all cancers and tissues. Among them were clusters of similar or different degrees of specificity, such as prostate / liver, prostate / colon / liver, etc. One subset of prostate markers remains undefined due to missing DMR sequences in reads aligned with other cancers.
[0336] [Table 9] JPEG0007949098000029.jpg239169JPEG0007949098000030.jpg232169JPEG0007949098000031.jpg237169JPEG0007949098000032.jpg121169
[0337] Example VI. To evaluate PCa detection in clinical culture media, we selected a set of high-performance PCa markers and conducted experiments in blinded, independent plasma samples.
[0338] For the development of the multiplex QuARTs-X (Quantitative Allele-Specific Real-Time Target and Signal Assay), we selected 25 DMRs / markers (see Table 8) that demonstrated the best combination of performance metrics suitable for analyte detection in complex biological media (e.g., blood plasma) and test platforms frequently used in other cancer plasma studies. Following initial in silico testing for DMR sequence uniqueness, design filters, and QC testing on pooled plasma controls, 17 designs were developed to test retrospectively collected and frozen plasma samples from the Mayo Prostate Cancer Biobank. Nine three-stage and one two-stage reactions were developed, each of which was included in a control β-actin assay and unaffected by methylation. Two additional process controls were also tested. The QuARTs-X assays are listed in Table 8 (see Table 6 for primer and probe information). The final marker strands (copies) were normalized to the β-actin control and expressed as % methylation. The top four markers were max.chr3.193, HES5, SLCO3A1, and TPM4_8047. Combined with rPart modeling, the sensitivity and specificity for detecting PCa in blood samples were 78% and 91%, respectively.
[0339] [Table 10]
[0340] Example VII. Treatment decisions for prostate cancer are often subjective and inaccurate, and are frequently guided by the Gleason grade. In discovery and early validation, methylated DNA markers (MDMs) were identified for their prognostic association (see Example I). Further experiments evaluated novel MDM levels in predicting biochemical recurrence using archived tissue from independent groups followed >12 years after radical prostatectomy (RP).
[0341] From 737 men who underwent radical prostatectomy (RP) in 2004, 446 were randomly selected, and 155 met quality criteria. Formalin-fixed paraffin-embedded (FFPE) tissue blocks were used. Expert pathologists re-examined all specimens in a blinded manner using tumors marked for the latest Gleason criteria and macrodissection. Genomic DNA was purified using the QiaAmp FFPE tissue kit (Qiagen) and quantified by Picogreen fluorescence. Because FFPE DNA could be highly degraded, specimens were tested for amplified genomic equivalents by a 100 bp β-actin amplification assay. The DNA was then treated with sodium bisulfite and purified (Zymo Research).
[0342] Twenty-three MDMs were selected and samples were tested. The 23 MDMs were identified by performing recurrent partition analysis (rPART) on independent tissue validation results using 73 MDMs. All patients used in this study (Example 1) had outcome data in their clinical records. Specifically, the experiment performed rPART (in silico) on 1000 bootstrap samples and searched for the most frequently appearing MDMs in the modeling tree. These were then ranked by frequency (high to low) and the top MDMs were selected (see Table 10). Blinded MSP assays were performed against dilutions of universal methylation standards, as well as appropriate negative and positive controls, as before. Untreated counts were normalized to the total β-actin count for each sample. Relapse was defined as PSA > 0.4 ng / mL. To assign relapse risk, the top MDMs were selected by a regression partition tree model and grouped by quartile (M1 (lowest) to M4 (highest)). Prognostic values for MDM and the Gleason grade group (GGG) were evaluated and compared based on their concordance with post-RP outcomes. The following markers were identified as optimal for predicting relapse rates: WNT3A, LOC100129726, FNBP1, GSDMD, ITPRIPL1, Chr1.61519554, and Chr17.77786040.
[0343] [Table 11] JPEG0007949098000035.jpg223169
[0344] Example VIII. Further experiments identified markers that could distinguish between 1) Gleason scores of 7 and 6 for PCa in prostate tissue, and 2) Gleason scores of 6 and PCa in non-cancerous prostate tissue. These experiments utilized QuARTs-X (Quantitative Allele-Specific Real-Time Targeting and Signaling Assay) (see, for example, U.S. Patent Application No. 15 / 335,096). DNA extraction Frozen DNA tissue samples with known clinical information were obtained from the Mayo Clinic repository. DNA was extracted from the tissues using the DNeasy Blood & Tissue kit from Qiagen, following the manufacturer's protocol. Approximately 100 ng of extracted DNA was advanced to the bisulfite conversion reaction. DNA bisulfite conversion and purification
[0345] [Table 12]
[0346] [Table 13]
[0347] The following procedure was used for bisulfite conversion and purification of DNA. Add 1.10 μL of the inhibitory solution to each well in the deep well plate (DWP). 2. Add 80 μL of each sample to the DWP. 3. Mix carefully by pipetting using a pipette set to 30-40 μL, avoiding foaming. 4. The DWP was sealed at 3000xg and centrifuged for 4.1 minutes. Incubate at 5.42°C for 20 minutes. 6. Add 120 μL of BIS SLN to each well. Cool for 7-8 minutes. 8. Incubate at 65°C for 75 minutes, stirring during the first 3 minutes. Add 9.750 μL of BND SLN. 10. Pre-mix the silica beads (BND BDS), then add 50 μL of silica beads (BND BDS) to the DWP wells. Mix on a heater shaker at 11.30°C and 1,200 rpm for 30 minutes. After allowing the beads to bind on the plate magnet for 12.5 minutes, aspirate the solution and discard it. After adding 13.1 mL of washing buffer (CNV WSH), transfer the plate to a heater shaker and mix at 1,200 rpm for 3 minutes. After allowing the beads to bind on the plate magnet for 14.5 minutes, aspirate the solution and discard it. After adding 15.0.25 mL of washing buffer (CNV WSH), transfer the plate to a heater shaker and mix at 1,200 rpm for 3 minutes. After the beads have been bound to the magnet for 16.2 minutes, the solution is aspirated and discarded. Add 17.0.2 mL of desulfonation buffer (DES SLN) and mix at 1,200 rpm for 7 minutes at 30°C. After the beads have been bound to the magnet for 18.2 minutes, the solution is aspirated and discarded. After adding 19.0.25 mL of washing buffer (CNV WSH), transfer the plate to a heater shaker and mix at 1,200 rpm for 3 minutes. After binding the beads on the magnet for 20.2 minutes, aspirate the solution and discard it. After adding 21.0.25 mL of washing buffer (CNV WSH), transfer the plate to a heater shaker and mix at 1,200 rpm for 3 minutes. After the beads have been bound to the magnet for 22.2 minutes, the solution is aspirated and discarded. 23. Transfer the plate to a heater shaker and allow it to dry by incubating at 70°C for 15 minutes while mixing at 1,200 rpm. 24. Add 80 μL of elution buffer (ELU BFR) to all samples in the DWP. Incubate at 65°C for 25 minutes while mixing at 25.1,200 rpm. 26. Manually transfer the eluate to a 96-well plate, seal the plate with a foil seal, and store at -80°C. 27. The recoverable / movable volume is approximately 65 μL. QuARTS-X for the detection and quantification of methylated DNA Multiplex PCR (mPCR) setup: 1. Prepare a 10-fold primer mixture containing forward and reverse primers for each methylated marker to a final concentration of 750 nM. Use 10 mM Tris-HCl, pH 8, and 0.1 mM EDTA as the diluent. 2. Prepare a 10-fold mPCR buffer containing 100 mM MOPS, pH 7.5, 75 mM MgCl2, 0.08% Tween20, 0.08% IGEPAL CA-630, and 2.5 mM dNTPs. 3. Prepare the mRNA master mix as follows:
[0348] [Table 14]
[0349] Thaw the 4-DNA and centrifuge the plate to precipitate. Add 5-25 μL of the master mix to a 96-well ABI Veriti plate. 6. Transfer 50 μL of each sample to each well and mix the samples by pipetting up and down several times. 7. Seal the plate with aluminum foil seal. 8. Place the heated lid inside the thermal cycler and proceed to the cycle using the following profile "QX12 cycle":
[0350] [Table 15]
[0351] 9. After incubation was complete, the amplicon was diluted 1 to 10 times as follows: a. Obtain a deep-well plate and transfer 180 μL of 10 mM Tris-HCl, pH 8, and 0.1 mM EDTA to each well. b.96 Carefully drill holes in the foil seal of the plate amplified by the well stamp. c. Mix 75 μL of amplified sample by repeating pipetting using a new tip and a 200 μL pipette set for 50 μL (without generating an aerosol) (do not use a shaker for mixing). d. Using a new tip and a 20 μL pipette set (which does not generate aerosols), add 20 μL of amplified sample to each pre-filled well. e. Mix the diluted samples by repeatedly pipetting using a new tip and a 200 μL pipette set for 100 μL (to avoid aerosol generation) (do not use a shaker for mixing). f. Seal the diluted plate with a plastic seal. Centrifuge the diluted plate at 1,000 rpm for 1 minute. h. Seal any remaining undiluted mPCR product with a new aluminum foil seal. Leave at -80°C. Manual Quarts assay setup: 1. Thaw the fish DNA diluent (20 ng / μL) and use it to dilute the plasmid calibrator required for this assay. Use the following table as a dilution guide:
[0352] [Table 16]
[0353] 2. Prepare a 10-fold triple Quartz oligo mixture using the following table for markers A, B, and C:
[0354] [Table 17]
[0355] 3. Use the following table to prepare the Quarts Master Mix:
[0356] [Table 18]
[0357] Using a 4-96 well ABI plate, pipette 20 μL of Quarts Master Mix into each well. Add 5-10 μL of appropriate calibrator or diluted mPCR sample. 6. Seal the plate with ABI transparent plastic seal. Centrifuge the plate for 7-1 minutes using 3000 rpm. 8. After placing the plate, activate the ABI thermal cycler while it is programmed to perform the following thermal protocol, "Quarts 5+40".
[0358] [Table 19]
[0359] A. Automated Quartz setup: Thaw 1-1 tube of fish DNA dilution (20 ng / μL) and 2 tubes of 1.62x oligo mixture to prepare the calibrator series and place it on the Hamilton STARlet Deck. Before placing the reagents on the 2-Hamilton STARlet Deck, vortex and centrifuge all reagents. 3. Place the deep-well plate containing the sample onto the magnet. 4. Place a full tray of 50 μL CORE tips on the deck, as shown in the diagram below. 5. Place 1000 μL of CORE tip on at least one entire row of deck, as shown in the diagram below. 6. With the barcode facing the front of the machine (relative to the A1 well in the rear left corner), place the empty ABI96 well plate on the STARlet deck as shown in the following diagram. 7. Place the reagents in the indicated carrier positions according to the on-screen deck layout and software instructions (see Figure 2 below). 8. Place two empty tubes with barcodes and no caps on the deck, as shown in the diagram below. 9-Execute the "QuARTSONLYV4.0_BA_20160127" method on Hamilton. 10. Once this method is complete, remove the 96-well Quartz plate and seal it with the clear plastic cover. Centrifuge the plate for 11-1 minutes using 3000 rpm. 12. Next, after placing the plate in the ABI thermal cycler, which is programmed to perform the following thermal protocol, start up the instrument: "Quarts5+40". result These experiments, 1) Specific methylated DNA markers (SERPINB9_3479, GRASP_0932, SLCO3A1_6187, ITPRIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487) distinguish very high-grade cancerous prostate tissue (e.g., Gleason score of 7.0 or higher (e.g., 7, 8, 9, 10)) from low-grade cancerous prostate tissue (e.g., Gleason score of less than 7 (e.g., 6)), and, 2) Specific methylated DNA markers (SERPINB9_3479, FLOT1_1665, HCG4P6_4618, CHST11_2206, MAX.chr12.485, GRASP_0932, GAS6_6425, MAX.chr3.193, MAX.chr2.971_3164, MAX.chr3.727_8028, HES5_0840, TPM4_8037, SLCO3A1_6187, ITP) RIPL1_1244, AKR1B1_3644, RASGRF2_6325, ZNF655_6075, PAMR1_7364, ST6GALNAC2_1113, CCNJL_9070, KCNB2_9128, IGFBP7_6412, and WNT3A_5487) distinguish cancerous prostate tissue (e.g., Gleason score of 6.0 or higher (e.g., 6, 7, 8, 9, 10) from non-cancerous prostate tissue) They identified it.
[0360] Table 11 shows the % methylation for normal tissue, % methylation for prostate tissue with a Gleason score of 6, and % methylation for prostate tissue with a Gleason score between 7 and 10 (table 12 provides oligo sequences; table 13 provides DMR information).
[0361] [Table 20]
[0362] Using a 100% cutoff, logistic regression analysis fit of % methylation compared to ACTB was used for this data, enabling prediction of cancer from normal with 98.5% sensitivity using two markers, FLOT1 and MAX.Chr3.193, which have AUC=0.99. For 6 vs 6+ prediction, logistic regression analysis fit of % methylation of nine markers (AUC=0.96) compared to ACTB predicted Gleason 6+ with 92.8% sensitivity and 91.7% specificity. The markers were GRASP, GAS6, MAX.chr3.193, MAX.chr2.971, TPM4, ITPRIPL2, AKR1B1, ZNF655, and WNT3A.
[0363] [Table 21] JPEG0007949098000046.jpg215169JPEG0007949098000047.jpg238169JPEG0007949098000048.jpg233169JPEG0007949098000049.jpg39169
[0364] [Table 22]
[0365] All publications and patents described in the above specification are incorporated herein by reference in their entirety for all purposes. Various modifications and variations of the compositions, methods, and uses of the described scientific and technological advances will be obvious to those skilled in the art without departing from the scope and spirit of the scientific and technological advances as described. Although the scientific and technological advances have been described in relation to specific exemplary embodiments, it should be understood that the present invention as described in the claims should not be unduly limited to such specific embodiments. In fact, various modifications of the methods described for carrying out the present invention that are obvious to those skilled in the art in pharmacology, biochemistry, medicine, or related fields are intended to be within the scope of the appended claims.
Claims
1. A method for characterizing a sample obtained from a subject who has or is suspected of having prostate cancer by determining the methylation levels of one or more genes, Treat the DNA from the above sample with a reagent that modifies the DNA in a methylation-specific manner; Amplifying the treated DNA using primers specific to at least one CpG site of one or more genes including GRASP; and A method comprising determining the methylation level of at least one CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, and / or bisulfite sequencing PCR.
2. The method according to claim 1, wherein the one or more genes described above further comprise at least one additional gene selected from GAS6, TPM4, MAX. chr3.193, WNT3A, ITPRIPL1, MAX. chr2.971, ZNF655, AKR1B1, and / or CHST11.
3. A primer specific to at least one CpG site in ZNF655 is capable of binding to an amplicon constrained by sequences including SEQ ID NOs: 210 and 211. A primer specific to at least one CpG site in WNT3A is, Sequence ID: It is possible to bind to an amplicon constrained by the sequence containing 232 and 233, A primer specific to at least one CpG site in CHST11 is capable of binding to an amplicon constrained by sequences including SEQ ID NOs: 85 and 86 or SEQ ID NOs: 156 and 157. A primer specific to at least one CpG site in AKR1B1 is capable of binding to an amplicon constrained by sequences including SEQ ID NOs: 201 and 202. A primer specific to at least one CpG site in GRASP is capable of binding to an amplicon constrained by the sequence containing SEQ ID NOs: 162 and 163. A primer specific to at least one CpG site in GAS6 is, SEQ ID NO: 1 It is possible to bind to an amplicon constrained by the sequence containing 65 and 166, A primer specific to at least one CpG site in MAX. chr3.193 can bind to an amplicon constrained by sequences including SEQ ID NOs: 174 and 175. It is Noh, A primer specific to at least one CpG site in MAX. chr2.971 can bind to an amplicon constrained by sequences including SEQ ID NOs: 198 and 199. It is Noh, A primer specific to at least one CpG site in TPM4 is, SEQ ID NO: 1 It is combinable to an amplicon constrained by sequences including 89 and 190; and / or A primer specific to at least one CpG site in ITPRIPL is capable of binding to an amplicon constrained by sequences including SEQ ID NOs: 195 and 196. The method according to claim 1 or 2.
4. The above method, The method according to claim 1, comprising amplifying the treated DNA using a primer specific to at least one CpG site in GRASP and a primer specific to at least one CpG site in CHST11.
5. The method according to claim 1, wherein the sample is a fecal sample, a urine sample, a blood sample, a gastrointestinal fluid sample, or a tissue sample.
6. The method according to claim 1, wherein the sample comprises cells, secretions, or tissues from the prostate, liver, bile duct, pancreas, stomach, colon, rectum, esophagus, small intestine, appendix, duodenum, polyps, gallbladder, anus, and / or peritoneum.
7. The method according to claim 1, wherein the sample comprises tissue or cells of the prostate.
8. The method according to claim 1, wherein the at least one CpG site is located in a coding region or a regulating region.
9. The method according to claim 1, wherein the reagent is a bisulfite reagent.
10. The method according to claim 9, wherein the above-mentioned bisulfite reagent comprises bisulfite, disulfite, hydrogen sulfite, or a combination thereof.
11. The method according to claim 1, wherein determining the methylation level of at least one CpG site in one or more genes includes determining a methylation score and / or determining a methylation frequency.
12. The method according to claim 1, wherein the methylation level of the at least one CpG site in one or more genes includes an increased methylation level compared to a control or reference methylation level of the at least one CpG site in one or more genes.
13. The method according to claim 1, wherein the methylation level of the at least one CpG site in one or more genes includes a methylation pattern that has been altered compared to a control or reference methylation pattern of the at least one CpG site in one or more genes.
14. The method according to claim 1, wherein determining the methylation level of at least one CpG site in one or more genes comprises determining the methylation level of a control or reference sample.
15. The above control sample is obtained from a subject who does not have cancer, according to the method of claim 14.
16. The method according to claim 1, wherein the one or more genes further comprises at least one additional gene selected from CHST11, FLOT1, hCG4P6, MAX. chr 12.485, GAS6, MAX. chr 3.193, MAX. chr 2.971, MAX. chr 3.727, HES5, TPM4, SLCO3A1, ITPRIPL1, AK R1B1, RASGRF2, ZNF655, PAMR1, ST6GALNAC2, CCN JL, KCNB2, IGFBP7, and / or WNT3A.
Citation Information
Patent Citations
Biomarkers for prostate cancer
JP2015527875A
Genome-wide analysis of palindrome formation and DNA methylation
WO2010138626A1
